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Summary 
Cells are commonly exposed to different types of genotoxic stress throughout 
their life cycles, and have therefore evolved mechanisms to initiate the DNA 
damage response (DDR) in order to maintain genomic integrity. If the DNA 
damage is too extensive to be repaired however, the cell undergoes 
programmed cell death. Recent studies have suggested that persistent DNA 
damage signaling induces cells to enter senescence and upregulate pro-
inflammatory cytokines such as interleukin (IL)-1 after a prolonged period of 
time, which in turn play a role in facilitating communication between 
damaged cells and their microenvironment. Despite these findings however, 
the immediate effects of genotoxic stress on cytokine secretion by the 
damaged cells are still not well understood.  
 Here, we report that genotoxic stress caused by chemotherapy activates 
DDR and induces damaged cells to enter apoptosis. Administration of 
bleomycin induces IL-1Ra secretion within 24 hours but not IL-1α, IL-1β or 
IL-1R1. Besides chemotherapy, IL-1Ra secretion is upregulated by other types 
of genotoxic stress stimuli including telomere dysfunction. Our data indicate 
that genotoxic stress-induced IL-1Ra expression occurs independently of 
transcriptional regulation, de novo protein synthesis and N-glycosylation, and 
IL-1Ra is released via the non-classical secretory pathway. IL-1 signaling does 
not play a role as blockade of IL-1 signaling by IL-1α or IL-1β neutralizing 
antibodies, or by ablating IL-1R1 did not affect chemotherapy-induced IL-1Ra 
secretion. Induction of IL-1Ra release by bleomycin is also independent of 
DDR signaling as inhibition of ATM and/or ATR or abrogation of p53 did not 
impair the increase in IL-1Ra secretion induced by bleomycin. We 
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subsequently demonstrate that bleomycin activates caspases that mediate the 
intrinsic apoptosis pathway, and chemotherapy-induced IL-1Ra secretion is 
dependent on caspase-9 activation and partially on caspase-3 activation. Our 
findings indicate that IL-1Ra secreted by bleomycin-treated cells is bioactive, 
and can impair IL-1-induced IL-6 gene expression, suggesting that IL-1Ra is 
secreted by the damaged cells as an immediate response to genotoxic stress in 
order to prevent or dampen inflammatory responses. 
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Chapter 1: Introduction 
1.1 Genotoxic stress inducers and their mechanisms of actions 
Cells are subjected to different kinds of genotoxic stress throughout their life 
cycles, resulting in DNA lesions that affect genomic DNA replication and 
transcription (van Vugt et al., 2005). If not repaired properly, such DNA 
lesions could result in mutagenesis including base transversions, transitions, 
frameshift mutations, or chromosomal aberrations, therefore leading to wide-
scale genomic aberrations that endanger the survival of the individual cell as 
well as of the organism. Studies have shown that genotoxic stress is induced 
by endogenous or exogenous sources (Bartek et al., 2004). Endogenous DNA 
damage occurs via physiological processes such as DNA replication or 
abortive topoisomerase activity, whereas exogenous sources like 
environmental toxic agents can induce DNA lesions as well. Although 
endogenous DNA damage occurs more frequently than exogenous DNA 
damage, more than 70% of human cancers are caused by exogenous sources of 
genotoxic stress.  
 
1.1.1 Exogenous sources of genotoxic stress 
Accidental or involuntary exposure to exogenous factors such as ultraviolet 
light, ionizing radiation, physical and chemical agents (e.g. alkylating 
compounds, polycyclic aromatic hydrocarbons) can cause genotoxic stress 
(Bartek et al., 2004). In cancer therapy, chemotherapeutic drugs are routinely 
used for their cytotoxic effects on cancer cells (Zhou and Bartek, 2004). Such 
drugs damage DNA directly by acting as alkylating agents, or indirectly by 
generating reactive metabolites or interfering with enzymes that regulate DNA 
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metabolism, such as DNA polymerases or topoisomerases. For instance, 
bleomycin causes single strand and double strand DNA breaks by generating 
free radicals (Smith et al., 1994). Produced by Streptomyces verticillis, 
bleomycin belongs to a family of basic glycopeptide-derived antibiotics and is 
a potent chemotherapy drug used in clinics for treatment of testicular cancer, 
non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and squamous cell 
carcinoma (Hay et al., 1991; Sidik and Smerdon, 1990).  
Several in vitro experiments demonstrated that bleomyin molecule has 
two main structural components – a bithiazole component that binds and 
intercalates into the DNA helix, therefore parting the DNA strands, and the 
pyrimidine and imidazole structures that bind iron (Hay et al., 1991). 
Bleomycin forms a metal coordination complex with iron and reacts with 
oxygen to generate a highly reactive species known as “activated bleomycin” 
(Smith et al., 1994). This complex then cleaves DNA in a sequence specific 
manner by inducing DNA double strand breaks at a primary site between a 
guanine and a pyrimidine. Activated bleomycin is subsequently regenerated 
and goes on to induce a secondary cleavage directly opposite the primary site, 
or on an adjacent base in the opposite strand, resulting in double stranded 
DNA breaks that are blunt-ended or have single-base 5’ overhangs (Povirk et 
al., 1989). Unlike most other chemotherapeutic drugs that are S-phase 
specific, bleomycin is capable of inducing chromosome- and chromatid-type 
aberrations when administered in any phase of the cell cycle (Povirk and 
Austin, 1991). Furthermore, administration of bleomycin before the S phase 
(i.e. G0 or G1 phase) causes chromosome-type aberrations, whereas 
administration of bleomycin in the S or G2 phase of the cell cycle induces 
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chromatid-type aberrations instead (Dresp et al., 1978; Povirk and Austin, 
1991). Bleomycin is therefore considered to be a radiomimetic 
chemotherapeutic drug (Povirk and Austin, 1991) as it resembles ionizing 
radiation, which also acts independently of S-phase and causes chromosomal 
aberrations. 
There are also other classes of chemotherapeutic drugs that act by 
interfering with DNA replication and repair processes. In particular, 
doxorubicin, also known as adriamycin, is a classical topoisomerase II poison 
(Burden and Osheroff, 1998). During DNA transcription or replication, 
topoisomerase enzymes unwind DNA helices by cleaving one strand of the 
DNA helix and by passing a second duplex through this transient cleavage, 
resulting in an intermediate called the “cleavable complex” (Liu et al., 1983; 
Tewey et al., 1984). Upon entering the cell nucleus, doxorubicin intercalates 
the DNA and prevents the cleaved duplex from re-ligating, therefore 
generating DNA double strand breaks. 
 
1.1.2 Endogenous sources of genotoxic stress 
Endogenous sources occur spontaneously, and are normally caused by the 
products of cellular metabolism, replication, or mitosis processes. In addition, 
endogenous genotoxic stress is also induced by aberrant activation of 
oncogenes in cancer, such as c-MYC. c-MYC protein is a transcription factor 
that plays a crucial role in cell growth, cell differentiation and apoptosis 
(Pelengaris et al., 2002) and it is one of the genes that are most commonly 
affected in cancer. Indeed, 70% of human cancers have deregulated expression 
of c-MYC and chromosomal amplifications and translocations of c-MYC have 
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also been found in several lymphoid, mesenchymal and epithelial 
malignancies (Evan and Littlewood, 1993; Henriksson and Luscher, 1996; 
Spencer and Groudine, 1991). Some human tumors have been shown to 
express a stabilized mutant form of c-MYC as well as exhibit aberrant 
activation of upstream pathways that stimulate growth. Overexpression of c-
MYC destabilizes the genome, which in turn induces DNA damage and causes 
tumorigenesis (Pusapati et al., 2006; Ray et al., 2006).  
Three mechanisms have been proposed to explain how c-MYC induces 
DNA damage. Firstly, c-MYC may indirectly disrupt the repair of DNA breaks 
by interfering with gene products involved in the homology-directed 
recombination, non-homologous end joining and/or single strand annealing, 
therefore increasing the frequencies of chromosomal breakages and 
translocations (Karlsson et al., 2003). Overexpression of c-MYC can also 
accelerate cell cycling through the G1/S phase and results in uncontrolled 
cellular proliferation and growth that leads to genomic destabilization (Felsher 
and Bishop, 1999). Secondly, c-MYC deregulation induces telomere and 
chromosome remodeling during interphase, leading to chromosomal 
rearrangements (Louis et al., 2005). Unlike telomeres of the normal cells that 
are organized in a unique 3D structure, tumors overexpressing c-MYC contain 
telomeric aggregates in the interphase nuclei due to end-to-end telomeric 
fusions of chromosomes, therefore resulting in a series of breakage-bridge-
fusion cycles, and eventually genomic instability. In addition to telomeric 
remodelling, c-MYC can also directly damage the genomic DNA by 
generating reactive oxygen species (ROS) (Dang et al., 2005; Hironaka et al., 
2003; Khanna and Jackson, 2001; Maciag et al., 2004) which induce DNA 
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breaks, base modifications and cross-linking of DNA (Ramana et al., 1998; 
Slupphaug et al., 2003). Generation of ROS by c-MYC however, may occur 
only at ambient oxygen saturation and/or in the presence of low serum (Ray et 
al., 2006). In addition, c-MYC overexpression in vivo generally induces 
widespread double strand DNA breaks independently of ROS production. 
Besides oncogene activation, dysfunctional telomeres were shown to 
be an endogenous source of DNA damage. Telomeres are specialized 
nucleoprotein complexes that consist of short tandem DNA repeats located 
specifically at ends of linear chromosomes, which distinguish normal 
chromosome ends from intrachromosomal DNA double strand breaks, and 
prevent improper repair and recombination between internal DNA breaks and 
native chromosomes or fusion of the chromosomal ends (Longhese, 2008; 
Maser and DePinho, 2004). Given their importance in maintaining 
proliferative capacity, appropriate gene expression and genome stability in the 
cells, structure of telomeres is therefore well conserved in eukaryotes.  
The process of maintaining telomere length is a dynamic one: 
shortening of telomeres is due to nucleolytic degradation and incomplete DNA 
replication whereas lengthening of a telomere is achieved partly by 
homologous recombination (Liu et al., 2007) or mainly by the action of 
specialized reverse transcriptases, otherwise known as telomerases (Greider 
and Blackburn, 1985). In yeast, telomerases preferentially act on telomeres 
with declining lengths (Teixeira et al., 2004), and as many as a hundred of 
nucleotides can be added to each telomere per cell cycle. Cell proliferation 
without adequate telomerase activity to replenish nucleotides that are lost 
during replication can eventually lead to telomere erosion. Maintenance of 
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telomeres is crucial for cellular survival as telomere dysfunction leads to 
inappropriate chromosome fusions and rearrangements, cell cycle arrest, 
senescence and/or apoptosis (Maser and DePinho, 2004). Like classical 
internal DNA lesions, dysfunctional telomeres or disruption of telomere 
replication process can lead to the activation of DNA damage response and 
DNA repair mechanisms. 
 
1.2 Cellular signaling pathways activated by genotoxic stress 
Given the myriad of exogenous and endogenous sources of genotoxic stress, it 
has been suggested that cells in the human body can experience up to 105 
incidences of DNA damaging events per day (Lindahl and Barnes, 2000). 
Numerous studies have hence focused on understanding how DNA lesions are 
detected and resolved at the molecular level. To deal with threats posed by 
DNA damage that could potentially affect an organism’s survival, cells 
therefore possess a complex network of signaling pathways to monitor 
chromosome structures, to initiate repair as well as to regulate the cell cycle 
progression in response to genotoxic stress. These mechanisms are 
collectively termed as the DNA damage response (DDR). 
Although different types of DNA lesions activate different kind of 
responses, these responses generally occur via a common pathway. In general, 
DDR is initiated by sensor proteins that recognize DNA lesions or stalled 
replication forks caused by DNA damage, and these sensor proteins in turn 
recruit and activate transducers that are critical in transducing DDR pathway 
by inducing effector proteins. These effector proteins then inhibit cell cycle 
progression and activate DNA repair mechanisms, or induce programmed cell 
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death if the DNA damage is too extensive to be repaired. Therefore, DDR 
prevents replication of damaged DNA and plays a crucial role in maintaining 
genome integrity.  
 
1.2.1 DNA damage response 
Signal transducers are conserved proteins with recognizable motifs, and are 
central in mediating signals for the DDR pathway. Phospho-inositide kinase 
(PIK)-related proteins, which comprise of ATM (Ataxia Telangiectasia, 
mutated) and ATR (ATM- and Rad3- Related) kinases in mammals and their 
homologues in yeast, have been identified to act as signal transducers in the 
DDR signaling pathway. ATM and ATR kinases share significant sequence 
homology and have several substrates in common. In addition, these two 
proteins have similar and overlapping functions, and they also cooperate with 
other proteins to initiate the DDR (Bartek and Lukas, 2007; Cimprich and 
Cortez, 2008; Kastan and Bartek, 2004; Shiloh, 2003). 
ATM kinase is preferentially activated by DNA double strand breaks, 
and is recruited to the site of damage within minutes of double strand break 
formation. ATM kinase is subsequently phosphorylated and activated, and 
remains in the activated state for several hours. ATR kinase on the other hand, 
is generally activated by stalled replication forks that occur during DNA 
replication, and has been shown to play an important role in maintaining 
genomic integrity during S phase of the cell cycle. In addition, it has been 
demonstrated that ATR kinase is activated by ultraviolet light, single strand 
DNA breaks, and chemical agents that interrupt DNA replication and rise to 
stalled replication forks. 
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Activation ATM and/or ATR kinases then lead to the phosphorylation 
of a number of downstream kinases including CHK1 and CHK2, which are 
serine/threonine kinases that do not share any structural similarity but have 
overlapping substrate specificity. Specifically, ATM kinase induces CHK2 
phosphorylation at threonine 68, thereby triggering homodimerisation and 
autophosphorylation of CHK2 at Thr383 and Thr387. When triggered by 
DNA lesions, ATR kinase preferentially phosphorylates CHK1 at serine 317 
and serine 345. Studies have shown that ATM and ATR kinases can also 
modulate the chromatin structure in response to DNA damage. This occurs by 
phosphorylating histone H2A variant (H2AX) at serine 139 on the chromatin 
region surrounding the DNA lesions, leading to ubiquitin adduct formation 
and recruitment of factors that promote the repair of double strand DNA 
breaks (Huen and Chen, 2008). Currently, more than 700 proteins involved in 
DNA replication and repair mechanisms have been identified to be substrates 
for ATM and ATR kinases. 
The activities of ATM and/or ATR kinases eventually lead to the 
recruitment of effector proteins to the sites of DNA damage, such as p53, 
Mouse double minute 2 (MDM2) and Nijmegen breakage syndrome 1 
(NBS1). CHK1 and CHK2 cooperate with ATM and ATR kinases to inhibit 
cyclin-dependent kinase (CDK) activity, of which part of this inhibitory effect 
is mediated by p53 activation (Bartek and Lukas, 2007; Kastan and Bartek, 
2004; Riley et al., 2008). In addition, targets of p53 activity such as p21 and 
14-3-3σ assist in maintaining cell cycle arrest at G1-S, intra-S or G2-M 
checkpoints, thus enabling the cell to repair any detected DNA lesion before 
resuming cell cycle progression (Bunz et al., 1998; Chan et al., 1999). The 
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role of Chk2 in transducing DDR signals is demonstrated in Chk2-/- 
thymocytes, which failed to stabilize and activate p53 transcription activity, or 
to induce apoptosis when exposed to ionizing radiation (Hirao et al., 2000). As 
both ATM kinase and its substrate, CHK2 can phosphorylate p53, this may 
constitute a synergistic effect to ensure that p53 is fully activated during DDR. 
Once the DNA breaks have been successfully repaired, DDR signaling 
mechanisms will be inactivated and the cell will re-enter cell cycle. On the 
other hand, unresolved DNA damage results in persistent DNA damage 
signaling that induces permanent state of cell cycle arrest known as cellular 
senescence or cell death by apoptosis (Figure 1.1).  
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Adapted and modified from Nature Reviews Cancer 12, 709 – 720 (2012)  
 
Figure 1.1: The DNA damage response. DNA damage sensors detect DNA 
double strand breaks and single strand breaks induced by stress inducers such 
as chemotherapy, telomere dysfunction or oncogene activation. This leads to 
the recruitment of ATM and ATR kinases. ATM and ATR kinases in turn 
phosphorylate the histone variant H2AX on the chromatin surrounding the 
DNA breaks. ATM and ATR kinases also respectively phosphorylate and 
activate downstream transducers CHK2 and CHK1, resulting in the 
recruitment and activation of effector proteins such as p53 and the cell 
division cycle 25 (CDC25) phosphatases. If the DNA breaks are successfully 
repaired, DDR signaling mechanisms will be inactivated and the cell will re-
enter cell cycle. On the other hand, unresolved DNA damage results in 
persistent DNA damage signaling that induces cellular senescence or 
apoptosis. 
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1.2.2 Apoptosis 
The term “programmed cell death” was first proposed by Lockshin and 
Williams in 1965 to describe the cell-intrinsic program that induced certain 
cells to die during tadpole and insect metamorphosis (Lockshin and Williams, 
1965). In 1972, another group of researchers (Kerr, Wyllie and Currie) coined 
the term “apoptosis” to describe cell death that is characterized by a set of 
unique morphological features (Kerr et al., 1972). The early features of 
apoptosis include shrinkage of cytoplasm and chromatin condensation 
(pyknosis), which can be observed by light microscope (Kerr et al., 1972). 
This is followed by extensive membrane blebbing, nuclear fragmentation and 
intranucleosomal DNA fragmentation. During apoptosis, the dying cells 
expose phosphotidylserine on their plasma membranes and eventually 
fragment into apoptotic bodies, which consist of membrane-enclosed 
organelles that are subsequently phagocytosed by macrophages and other 
antigen presenting cells (Wyllie, 1980). 
Apoptosis is a controlled and energy-dependent process that does not 
induce inflammatory responses as the cellular constituents are not released 
into the surroundings and the apoptotic bodies are rapidly engulfed by 
phagocytes. In addition, the phagocytes do not release any anti-inflammatory 
cytokines upon engulfing the cells (Kurosaka et al., 2003; Savill and Fadok, 
2000). It has been suggested that apoptosis is necessary for proper 
development and homeostasis in order to maintain tissues. In addition, 
extensive DNA damage due to ionizing radiation or chemotherapy induces 
apoptosis to prevent inappropriate replication of damaged DNA. Deregulated 
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programmed cell death on the other hand, leads to diseases such as cancer, 
autoimmunity and neurodegenerative diseases. 
 
1.2.2.1 Caspases 
The mechanism for apoptosis was first elucidated in Caenorhabditis elegans 
(Xue et al., 1996; Yuan et al., 1993), where somatic cells invariantly die as 
part of the development process. It was subsequently discovered that caspases 
and B cell lymphoma 2 (Bcl-2) family members, which are mammalian 
homologues of ced-3 and ced-9 in C. elegans, are the key molecules that 
orchestrate and execute the apoptotic response (Gross et al., 1999; Hengartner 
and Horvitz, 1994; Yuan et al., 1993). Caspases refer to cysteine proteases that 
cleave after an aspartate residue in their substrates (Alnemri et al., 1996) and 
are conserved across species from yeast Saccharomyces cerevisiae (Madeo et 
al., 2002) to humans. 14 mammalian caspases have been identified so far, with 
11 being found in humans (caspase-1-10 and caspase-14) (Alnemri et al., 
1996; Pistritto et al., 2002; Shi, 2002b). 
The backbone structure is highly similar among the caspases with the 
key structural differences located at the catalytic sites (Wei et al., 2000). An 
active caspase composes of two large (~20kDa) and two small (~10kDa) 
subunits; one large subunit and one small subunit form a monomer. Each 
monomer comprises of 6 antiparallel β-strands and is held together with 
another monomer by hydrophobic interactions to form a continuous 12-
stranded central β-sheet that is surrounded by several α-helices and shorter β-
strands. Four loops (L1-L4) protrude out at opposite ends of this β-sheet, 
forming the two active sites of most caspases except for caspase-9, which has 
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only one active centre (Renatus et al., 2001). It has been shown that L1 loop 
and part of L2 loop originated from the large subunit, whereas L3 and L4 
loops are derived from the small subunit. L1 and L4 loops come together to 
form the groove that binds the substrate while L2 loop contains the catalytic 
cysteine reside and L3 loop forms the base (Shi, 2002b). Unlike L2 and L4 
which exhibit more variation, the length and composition of L1 and L3 of the 
catalytic site are relatively conserved (Shi, 2002b). Activation of caspases is 
mediated by cleavage of L2 loop from the monomer, thus releasing the N- and 
C-termini of the small and large subunits respectively. The N-terminal 
segment contains the catalytic cysteine residue while the C-terminal segment 
serves to maintain and support the active-site conformation of the other 
monomer (Shi, 2002b). 
The active-site loops L1-L4 give rise to substrate binding sites (S4-S3-
S2-S1), which determine the sequence specificity for substrate binding. 
Caspases possess similar S1 and S3 sites while S2 and S4 locations are 
conserved among the caspases (Shi, 2002b). Studies demonstrated that 
caspases can recognize four contiguous amino acids N-terminal to the scissile 
bond (P4-P3-P2-P1) in their substrates, and cleave after an aspartate residue at 
the P1 position (Shi, 2002b). The unique substrate specificity of the caspase 
family is determined by the S1 binding pocket, whose conformation limits P1 
position of the substrate to an aspartate residue (Barrett and Rawlings, 2001). 
On the other hand, a wide variety of amino acids are accepted at P2 position as 
the P2 side chain faces outside of the catalytic site (Thornberry et al., 1997). 
Glutamate residue is preferred at P3 and this interaction is speculated to 
stabilize the positioning of the substrate in the substrate-binding site 
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(Thornberry et al., 1997), while P4 position determines the substrate 
selectivity of different caspases. 
Based on their substrate preferences, the caspases can therefore be 
categorized into three main groups: caspase-1, -4, and -5 form class I caspases 
that favor substrates that have bulky and hydrophobic side chains in the P4 
position (optimal sequence of WEHD), class II consists of caspase-6, -8, -9 
and -11 that prefer substrates with (L/V)EXD in P4-P3-P2-P1 positions, and 
the last group composes of caspase-2, -3 and -7 which bind and cleave 
substrates with DEXD sequences, where X refers to V, T or H (Kang et al., 
2000; Thornberry et al., 1997). 
 
1.2.2.2 Initiator and effector caspases 
In mammals, apoptotic caspases are divided into two groups – initiator 
caspases (caspase-2, -8, -9, and -10) and effector caspases (caspase-3, -6 and -
7). As compared to the effector caspases, the initiator caspases have longer 
prodomains as their prodomains contain one or more adaptor domains that are 
important for the interactions with other adaptor molecules, such as the death 
effector domain (DED) for caspase-8 and -10, and the caspase activation and 
recruitment domain (CARD) for caspase-1, -2, -4, -5, -9, -11 and -12. In 
contrast, effector caspases have shorter prodomains of about 20 - 30 amino 
acid residues. 
Caspases are first synthesized as inactive enzymes or zymogens, each 
containing a N-terminal prodomain, followed by the large and small subunits. 
A spacer may be present between the subunits for some caspases. Proteolytic 
cleavage of caspase results in separation of the large and small subunits 
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followed by the prodomain (Ramage et al., 1995; Yamin et al., 1996). Caspase 
activation occurs in a sequential manner in which initiator caspases are first 
activated in respond to apoptotic signals, followed by the activation of effector 
caspases. The initiator caspases are activated by autocatalytic intrachain 
cleavage. The activated initiator caspases subsequently cleave the effector 
caspases at specific internal aspartate residues and separate the large (~p20) 
and small (~p10) subunits, which then assemble caspase monomers. As the 
executioner caspases are activated in trans by a heterologous caspase, this 
process is also known as ‘transactivation’. Such sequential activation of 
caspases leading to cell death enables caspase activity to be regulated at 
multiple levels. The ability of initiator caspases to autoactivate suggests that 
there is residual activity present in these zymogens. Since initiator caspases 
play a critical role in initiating apoptosis, several mechanisms are in place to 
keep this group of caspases in check. For instance, proteolysis of caspase-9 is 
not necessary for its activation (Renatus et al., 2001; Rodriguez and Lazebnik, 
1999; Stennicke et al., 2000). Instead, caspase-9 is activated by allosteric 
regulation, which requires the assembly of a multi-component complex known 
as the apoptotic-protease-activating factor-1 (APAF1) that also binds to 
cytochrome c (Adams and Cory, 2002; Shi, 2002a).  
Effector caspases carry out apoptosis by acting upon a broad spectrum 
of cellular targets to induce cell death, including other caspases (Hirata et al., 
1998). For instance, caspase-9 can cleave caspase-3 as well as caspase-7, and 
activated caspase-3 can in turn process caspase-9, therefore generating a 
positive feedback loop that amplifies the initial apoptotic signals (Slee et al., 
1999). Effector caspases also mediate the proteolysis of several proteins 
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involved in apoptosis, maintenance of cell structure and DNA repair and this 
is important for the execution of apoptosis signaling. Besides apoptosis, recent 
studies show that caspase-1, -11, and -5 also mediate inflammatory responses, 
suggesting that caspases can regulate pathways other than inducing cell death. 
 
1.2.2.3 Extrinsic and intrinsic pathways of apoptosis 
Depending on the death stimuli, apoptosis is activated via the extrinsic 
pathway or the intrinsic pathway. The former is initiated by binding of the cell 
surface death receptors to extracellular death ligands, therefore triggering the 
downstream signaling cascades (Nagata, 1999), whereas the latter is 
stimulated by signals within the cell, such as oncogene activation, DNA 
damage and genotoxic drugs. 
Intrinsic apoptosis pathway is orchestrated by mitochondria, and 
activation of this pathway results in the release of several proteins from the 
mitochondrial intermembrane space into the cytoplasm. These proteins include 
cytochrome c, SMAC (second mitochondria-derived activator of 
caspases)/DIABLO (direct inhibitor of apoptosis (IAP)-binding protein with 
low pI), AIF (apoptosis-inducing factor), EndoG (endonuclease G) and 
OMI/HTRA2 (high-temperature-requirement protein A2) (Wang, 2001). 
Cytochrome c binds to APAF1 and induces it to undergo conformational 
change. APAF1 then binds to ATP/dATP and assembles into an apoptosome 
(Jiang and Wang, 2000; Li et al., 1997). The apoptosome is made up of 7 
Apaf-1 molecules, each bound to a molecule of cytochrome c and a dimer of 
caspase-9 (Acehan et al., 2002; Cain et al., 2000). The multimeric complex 
subsequently activates initiator caspase-9 by promoting homodimerisation and 
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activation of caspase-9, therefore increasing its activity by 1000-fold (Renatus 
et al., 2001; Rodriguez and Lazebnik, 1999; Shiozaki et al., 2002). 
Extrinsic apoptosis pathway is triggered when the death receptors are 
stimulated. The family of death receptors includes CD95/Fas/Apo1, TNFR1, 
TNFR2, DR3/Wsl-1/Tramp, DR4/TRAIL-R1, DR5/TRAIL-
R2/TRICK2/Killer and DR6. These receptors contain multiple cysteine-rich 
repeats in their extracellular domains and death domains (DD) in their 
cytoplasmic portions, which mediate protein-protein interactions. Ligation of 
the death receptors leads to multimerisation of these receptors, forming a 
homotrimeric ligand-receptor complex that in turn recruits adaptor molecules 
such as Fas associated death domain (FADD). Caspase-8 subsequently binds 
to FADD at the N-terminus via its DED region and forms an oligomeric death-
inducing signaling complex (DISC) (Muzio et al., 1996; Peter and Krammer, 
2003). DISC formation results in autocatalytic activation of caspase-8, which 
then activates executioner caspase-3 by proteolytic cleavage. It has been 
suggested DISC formation facilitates intermolecular processing of caspase-8 
by increasing the local concentration of caspase-8 zymogens (Muzio et al., 
1998) (Figure 1.2). 
Studies have shown that in certain cell types, crosstalk between 
intrinsic and extrinsic pathways occurs via caspase-8-mediated cleavage of a 
BH3-only member of Bcl-2 family of proteins, BH3-interacting death domain 
agonist (Bid) (Li et al., 1998; Luo et al., 1998). This probably occurs due to 
insufficient amount of active caspase-8 or executioner caspases being 
produced. When cleaved, Bid translocates to the mitochondria and mediates 
the release of mitochondrial proteins such as cytochrome c via oligomerisation 
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of pro-apoptotic Bcl-2 family members Bak and Bax (Cory and Adams, 2002). 
In addition, experiments done using cell-free assays showed that caspase-9 
induces activation of caspase-8 and caspase-10 in an indirect manner. This 
occurs when caspase-9 activates caspase-3, which in turn activates caspase-2 
and caspase-6. Caspase-6 then cleaves and activates caspase-8 and caspase-10 
(Slee et al., 1999). 
‘Point-of-no-return’ refers to the event in apoptosis signaling where 
apoptosis still takes place despite the withdrawal of death signals. It generally 
occurs after cytochrome c release and during activation of effector caspases. 
Inhibition of caspase activation has been shown to delay such commitment to 
die until the depolarization of mitochondria occurs (Deshmukh et al., 2000). 
Since release of cytochrome c eventually results in an irreversible loss of 
mitochondrial respiration and function, this suggests that the ‘point-of-no-
return’ event is made up of two parts: caspase activation which occurs rapidly 
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Adapted and modified from 
 Nature Reviews Molecular Cell Biology 4, 552 – 565 (2003) 
 
Figure 1.2: Apoptosis pathways. The extrinsic pathway is initiated upon the 
ligation of death receptors. This leads to the formation of DISC, which in turn 
activates procaspase-8. Active caspase-8 then cleaves and activates procaspse-
3, which acts as an executioner caspases that mediate apoptotic signaling by 
cleaving a number of target proteins. This eventually leads to the demise of 
the cell. On the other hand, the intrinsic pathway is mediated by the 
mitochondria, where Apaf-1, cytochrome c and procaspase-9 form the 
cytosolic apoptosome complex. This results in the activation of procaspase-9, 
which then activates procaspase-3. Crosstalk between the two apoptosis 
pathways occurs when caspase-8 cleaves Bid, which in turn induces the 
release of mitochondrial proteins such as cytochrome c via oligomerisation of 
pro-apoptotic Bcl2 family members Bak and Bax. 
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1.3 Genotoxic stress and inflammation 
Recently, a link between genotoxic stress and inflammation was demonstrated 
in a study, which shows that senescent cells express a complex phenotype 
known as senescence-associated secretory phenotype (SASP) (Coppe et al., 
2008). When induced by genotoxic stress of sufficient magnitude such as 
ionizing radiation and DNA-damaging chemotherapeutic agents, these 
damaged cells enter cellular senescence after 7 to 10 days and secrete a 
number of inflammatory and immunomodulatory factors that may enable them 
to communicate with their environment on their compromised status. This is 
however, a response that is specific for senescent cells as damaged cells that 
were transiently arrested, but resumed growth after 24 to 48 hours did not 
develop SASP. Surprisingly, these cytokines promoted an epithelial-
mesenchyme transition and invasiveness when cultured with premalignant 
epithelial cells, suggesting that these factors could potentially alter the tissue 
microenvironment. It is subsequently found that DDR markers such as ATM 
and CHK2 are required to initiate and maintain the secretion of such factors 
(Rodier et al., 2009; Yu et al., 2013), and these cytokines in turn, reinforce 
cellular senescence (Acosta et al., 2013). Interestingly, p53 function is not 
required to induce or maintain the secretion of the inflammatory cytokines, but 
is essential to limit the inflammatory responses (Coppe et al., 2008). 
Furthermore, the loss of p53 intensified the pro-malignant effects of the 
secreted factors, suggesting that p53 limits the inflammatory responses 
induced by genotoxic stress.  
The interplay between DDR and inflammation is also demonstrated in 
another study, which shows that restoration of endogenous p53 expression in 
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p53-deficient tumors induces the tumor cells to senesce, and the senescent 
cells in turn secreted several inflammatory cytokines (Xue et al., 2007). In 
addition, the immunohistochemical stainings revealed that there was an 
increase in immune infiltration following p53 reactivation, suggesting that the 
inflammatory responses triggered an immune response that was specific to the 
tumor cells, leading to tumor regression. Moreover, additional studies revealed 
that p53-restored tumor cells secreted factors that influenced polarization of 
macrophages to tumor-inhibiting M1 phenotype that are capable of 
eliminating the senescent tumor cells (Lujambio et al., 2013). This concept is 
otherwise known as immunosurveillance (Dunn et al., 2004).  
Despite these findings however, it is still not well understood if cells 
secrete factors to modulate inflammation as an immediate response to 
genotoxic stress (within 48 hours after induction of genotoxic stress) and if so, 
which are the factors being released and how do these factors in turn, 
modulate inflammatory responses. A number of studies highlighted the 
importance of interleukin-1 (IL-1) in mediating genotoxic-stress induced 
inflammatory responses. For instance, IL-1 has been shown to be the potent 
inducer of senescence-associated secretion of pro-inflammatory cytokines 
(Acosta et al., 2013; Orjalo et al., 2009). Moreover, IL-1 signaling reinforces 
cellular senescence, and ectopic expression of IL-1α recapitulates senescence-
associated phenotype (Acosta et al., 2013). Our initial analyses based the 
microarray data derived from mice with functional or dysfunctional telomeres 
(Begus-Nahrmann et al., 2009) also suggested that the receptor for IL-1 
signaling (IL-1R1) might be regulated by genotoxic stress (data not shown). 
Given the ability of IL-1 to activate innate immune cells as well as to promote 
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B and T cell development and responses, we therefore decided to study the 
possibility of IL-1 signaling being modulated as an immediate response to 
genotoxic stress. 
 
1.4 IL-1 family 
IL-1 was first described in the early 1980s for its functions in inflammation 
and immunity (Dinarello, 1994). It was previously known under several 
names, including lymphocyte-activating factor, catabolin as it plays a role in 
the breakdown of connective tissue, and endogenous pyrogen as it causes 
fever. IL-1 affects most types of cells in the body and induces inflammation in 
tissues (Dinarello, 2005). In addition, IL-1 is inducible by several infectious 
agents and can be detected at elevated concentrations in patients with 
autoimmune diseases and sterile inflammation.  
IL-1 refers to two proteins, IL-1α and IL-1β, which are encoded by 
different genes but share similar and overlapping activities (Dinarello, 1996; 
Dinarello, 2009). Cells of mesenchymal origin, such as keratinocytes and 
endothelial cells, produce IL-1α. IL-1α possesses a nuclear localization 
sequence in the prodomain, and is found in the cytosol as well as in the 
nucleus, where it interacts with the chromatin (Cohen et al., 2010). IL-1α is 
therefore known as a “dual-function” cytokine - it induces downstream 
signaling by binding to the cell surface receptor, and acts as a transcription 
factor that regulates cellular senescence and cell survival (Buryskova et al., 
2004; Werman et al., 2004). IL-1α is also a critical mediator of inflammation 
when released by necrotic cells (Chen et al., 2007). On the other hand, IL-1β 
is mainly secreted by monocytes and macrophages (Kurt-Jones et al., 1985), is 
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detected in the systemic blood circulation and mediates systemic inflammatory 
responses. In contrast, IL-1α is associated with the plasma membrane and 
therefore exerts its effects in an autocrine and paracrine manner. IL-1β has 
hence been associated with a number of autoinflammatory diseases and is a 
therapeutic target in several clinical trials (Dinarello, 2011). Besides being 
released in a different manner, IL-1α and IL-1β are also differentially 
regulated during development and in response to certain extracellular signals 
(Rausch et al., 1994; Sims and Smith, 2010). 
IL-1 receptor antagonist (IL-1Ra) is a structural variant of IL-1 which 
does not induce signaling when binds to the receptor (Arend, 1993; Arend et 
al., 1998). Since IL-1Ra binds to the same receptor as IL-1 with similar 
avidity, it acts as an endogenous inhibitor that competes with IL-1 for binding 
to the receptor and is important for regulating the inflammatory effects of IL-
1. IL-1Ra exists in two forms - a secreted isoform (sIL-1Ra) and an 
intracellular isoform (icIL-1Ra). The sIL-1Ra isoform possesses a signal 
peptide and is variably glycosylated to give rise to a 22 – 25 kDa protein 
(Eisenberg et al., 1990; Hannum et al., 1990). It is mainly produced by 
monocytes and macrophages, as well as by cells that synthesize IL-1. sIL-1Ra 
is also released by the liver as acute phase proteins, and may play a role as a 
systemic anti-inflammatory protein (Gabay et al., 2001; Gabay et al., 1999; 
Gabay et al., 1997b). In contrast, icIL-1Ra does not have a leader peptide, and 
is constitutively expressed by keratinocytes and other epithelial cells in the 
cytoplasm as a non-glycosylated protein. icIL-1Ra consists of a number of 
subtypes generated by alternative splicing and/or by alternative translation 
initiation. Like its secreted counterpart, icIL-1Ra functions as an extracellular 
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receptor antagonist of IL-1 when released from the cells under specific 
conditions. In addition, icIL-1Ra can inhibit IL-1α from binding to the nuclear 
DNA (Arend, 1993; Haskill et al., 1991). Some studies have also suggested 
that icIL-1Ra has additional functions independent of IL-1 regulation, 
however this is currently not well understood. 
Type I IL-1R (IL-1R1) is the receptor that mediates IL-1 signaling by 
binding to IL-1α, IL-1β and IL-1Ra (Sims et al., 1988). It contains three 
extracellular immunoglobulin (Ig) domains and a Toll/IL-1R resistance (TIR) 
cytoplasmic domain, and is constitutively expressed at low levels on most 
cells. Type II IL-1R (IL-1R2), like IL-1R1, binds to IL-1, especially IL-1β 
(McMahan et al., 1991; Stylianou et al., 1992). Although IL-1R2 possesses a 
similar extracellular domain as IL-1R1, its cytoplasmic domain is truncated 
and is unable to signal. IL-1R2 therefore plays a role in limiting IL-1 signaling 
by acting as a decoy receptor. IL-1R2 is mainly expressed by IL-1 producing 
cells like monocytes and B cells, and can be shed by cells as a soluble protein. 
IL-1 receptor accessory protein (IL-1RAcP) is homologous to IL-1R1 and has 
been demonstrated to be important for IL-1 signaling (Greenfeder et al., 
1995). It is recruited when IL-1R1 binds to IL-1α, IL-1β and IL-1Ra 
(Eisenberg et al., 1991) (Figure 1.3). 
The IL-1 family members share highly conserved gene structures. 
Besides conservation of some of the intronic positions, they also share similar 
amino sequences that contribute to the subsequent protein structures. This 
suggests that the IL-1 family is likely to have risen from duplication of a 
common ancestral gene (Taylor et al., 2002). Except for IL-18 and IL-33, all 
IL-1 family genes are clustered within a 400 kb region on human chromosome 
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2, (Nicklin et al., 2002; Taylor et al., 2002). The receptors belonging to the IL-
1 family include IL-18R and its accessory protein AcPL, ST2, IL-1 receptor-
related protein-2 (IL-1Rrp2), IL-1 receptor accessory protein-like (IL-
1RAPL), three immunoglobulin IL-1 receptor-related (TIGIRR), and a single 
immunoglobulin IL-1 receptor-related (SIGIRR) (Sims, 2002). These 
receptors contain a TIR cytoplasmic domain and three Ig domains, except for 
SIGIRR, which has only one Ig domain (Polentarutti et al., 2003). In addition, 
IL-1RAcP is a chain used in common by IL-1R1, IL-1Rrp2 and ST2. 
IL-18 binds to the receptor complex comprising of IL-18R and AcPL 
and is a pro-inflammatory cytokine that is produced by macrophages, dendritic 
cells and epithelial cells during inflammation. In contrast, IL-37 (also known 
as IL-1F7) is anti-inflammatory in nature, and it inhibits innate immune 
responses by reducing inflammatory responses to Toll-like receptor (TLR) 
agonists, IL-1 and tumor necrosis factor (TNF) (Nold et al., 2010; Sharma et 
al., 2008). Though IL-37 also binds to IL-18R, however, this complex does 
not recruit AcPL (Boraschi et al., 2011). In addition, IL-37 binds to IL-18 
binding protein (IL-18BP), a distant relative of the IL-1R family. Like IL-1α, 
IL-37 acts as a “dual-function” cytokine, and is expressed by human 
monocytes and keratinocytes (Bufler et al., 2002; Busfield et al., 2000). Till 
now, the mouse orthologue of IL-37 has not been discovered.  
IL-36α, IL-36β and IL-36γ, which were originally known as IL-1F6, 
IL-1F8 and IL-1F9, are identified as ligands for IL-1Rrp2 (Dinarello et al., 
2010). These cytokines are highly expressed by the skin tissues, and 
monocytes can also be induced to express these cytokines (Dunn et al., 2001; 
Sims and Smith, 2010). The role of IL-36Ra (also known as IL-1F5) as pro-
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inflammatory or anti-inflammatory cytokine is still not well understood as 
while it has been shown to induce IL-4 by binding to SIGIRR in the brain, IL-
36Ra can also inhibit the pro-inflammatory effects of IL-1F6 in skin 
inflammation (Blumberg et al., 2007; Costelloe et al., 2008) (Figure 1.3). 
IL-33 (also know as IL-1F11) is expressed by several cell types, and 
binds to both ST2 and IL-1RAcP (Schmitz et al., 2005). Similar to IL-1α, IL-
33 is a nuclear protein that acts as a danger signal when released by dying 
cells (Carriere et al., 2007). As T-helper 2 (Th2) cells express high levels of 
ST2, IL-33 IL-33 is a potent activator of Th2 cells and plays a role in 
regulating inflammatory responses during allergy. Furthermore, studies have 
shown that cells shed soluble ST2 to bind and block IL-33 signaling during 
allergic airway inflammation (Hayakawa et al., 2007). 
Epithelial cells express SIGIRR, which impairs signaling responses to 
IL-1, IL-18, IL-33, IL-36α, IL-36β, IL-36γ and even to TLR agonists 
(Polentarutti et al., 2003; Wald et al., 2003). Mice that are deficient in SIGIRR 
displayed heightened inflammatory responses during diseases like 
inflammatory bowel disease and asthma, and have higher propensity to 
develop colon cancer due to uncontrolled inflammation (Garlanda et al., 
2009). Currently, the functions for IL-1RAPL and TIGIRR are not well 
understood, although mental retardation has been associated with a mutant 
form of IL-1RAPL (Sana et al., 2000). 
 




Figure 1.3: Diagrammatic representation of IL-1 family members. (A) IL-
1R1 binds to IL-1α or IL-1β, and this receptor complex recruits IL-1RAcP. A 
signaling platform is thus formed, leading to the recruitment of MyD88 and 
IRAKs, which trigger downstream signaling. IL-1R1 binds and is stimulated 
by both immature and mature forms of IL-1α. (B) Binding of IL-1Ra to IL-
1R1 does not give rise to any signal because this complex does not recruit IL-
1RAcP. (C) IL-1R2 does not possess a TIR cytoplasmic domain, thus binding 
of IL-1 to this receptor does not trigger IL-1 signaling. (D) SIGIRR possess an 
altered TIR domain (TIRb) and does not transduce IL-1 and TLR signaling. 
(E) IL-36α, IL-36β and IL-36γ bind to IL-1Rrp2 and stimulate downstream 
signaling. (F) Similar to IL-1Ra, IL-36Ra binds to IL-1Rrp2 but does not 
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1.4.1 IL-1 effects 
IL-1 signaling pathway is mediated via activation of nuclear factor-κB (NF-
κB), and IL-1 also activates three types of mitogen-associated protein kinases 
(p42/p44, p38, and Jun N-terminal kinase) (O'Neill et al., 1990). IL-1 binds to 
IL-1R1 and induces recruitment of IL-1RAcP, thereby bringing the two TIR 
domains together to form a signaling platform, which in turn, recruits myeloid 
differentiation factor 88 (MyD88) (Brikos et al., 2007; Deng et al., 2000). IL-1 
receptor associated kinase 1 (IRAK1) and IRAK4 are subsequently recruited 
via their death domains, after which they dissociate from MyD88 and bind to 
tumor necrosis factor receptor (TNFR)-associated factor 6 (Traf6) (Deng et 
al., 2000). Traf6 is an E3 ubiquitin ligase that auto-ubiquitinates itself by 
attaching K63-polyubiquitin chains. Transforming growth factor β-activated 
protein kinase (TAK1), together with TAK1-binding protein 2 (TAB2) and 
TAB3 then interact with ubiquitinated Traf6 via the nuclear zinc finger motifs 
(Ninomiya-Tsuji et al., 1999). This activates TAK1, which then binds to the 
complex consisting of the scaffold protein NF-κB essential modulator 
(NEMO) and the inhibitor of NF-κB (IκB) kinase (IKK). Studies have shown 
that TAK1 also interacts with kinases other than NEMO and IKK to mediate 
the activation of p38 and JNK. 
Besides activation via the Traf6/TAK1 pathway, IKK complex is also 
activated by IRAK1. In this case, IRAK1 is polyubiquitinated by two proteins, 
Pellino-1 and Pellino-3b, and this leads to the recruitment of NEMO (Butler et 
al., 2007; Conze et al., 2008; Ordureau et al., 2008). Transcription factors such 
as NF-κB and API are subsequently translocated into the nucleus to activate 
the expression of several pro-inflammatory genes like TNF-α, IL-6 and IL-12 
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(Akira, 2000; Wesche et al., 1997). Since IL-1 is also a target gene of NF-κB 
transcription activity, this establishes a positive feedback loop that maintains 
and amplifies the initial inflammatory response induced by IL-1 (Figure 1.4). 
  




Figure 1.4: IL-1-induced IL-1 synthesis, processing and release. (1) 
Binding of IL-1α or IL-1β to IL-1R1 induces the recruitment of IL-1RAcP. (2) 
This brings the intracellular TIR domains of both receptors in close proximity 
together. (3) The TIR domains form a signaling platform, which recruits 
MyD88, followed by phosphorylation of IRAKs and IKKβ. (4) IL-1β 
transcription is initiated by NF-κB. (5) IL-1β precursor is synthesized from the 
IL-1β mRNA. (6) Accumulation of extracellular ATP that is released from 
activated monocyte or macrophages. (7) ATP binds and activates the P2X7 
receptor. (8) This leads to the efflux of intracellular potassium ions. (9) The 
efflux of intracellular potassium ions results in a decrease in intracellular 
potassium levels. (10) This triggers the oligomerisation of the components of 
inflammasome, which in turn activates procaspase-1. (11) Active caspase-1 
found in the secretory lysosome cleaves and activates the IL-1β precursor. 
(12) Intracellular calcium levels increase due to an influx of extracellular 
calcium ions. (13) This triggers a series of events, leading to the exocytosis of 
the secretory lysosomes. (14) Active caspase-1 also cleaves and activates the 
IL-1β precursor found in the cytosol. (15) Mature IL-1β is released from the 
cytosol via microvesicles or when there is a loss in membrane integrity. 
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1.4.2 Regulation of IL-1 expression 
Since IL-1 family consists of potent pro-inflammatory cytokines that affects 
nearly every cell type, these cytokines are usually expressed at low levels and 
are tightly regulated at both transcriptional and translational levels (Dinarello, 
1996; Dinarello, 2009). In addition, there are several mechanisms that regulate 
the processing and secretion of these cytokines, as well as the expression of 
their surface receptors, soluble receptors and receptor antagonists. 
 
1.4.2.1 Processing and secretion of IL-1 family members 
IL-1β and IL-18 possess prodomains at their amino termini and require 
proteolytic processing by caspase-1 to generate mature, biological active 
proteins (Martinon et al., 2009). Caspase-1 in turn, is activated by the 
inflammasome, which is a group of highly specialized proteins consisting of 
an inflammasome sensor molecule like NOD-, LRR- and pyrin domain-
containing 1 (NLRP1) or NLRP3, an adaptor protein termed apoptosis-
associated speck-like protein containing CARD or also known as ASC, and 
caspase-1. ASC is encoded by PYCARD gene and comprises of two death-
fold domains - the pyrin domain and CARD. It is identified as the adaptor 
protein that connects the inflammasome sensor molecule to caspase-1. 
Specific intracellular signals such as a decrease in the intracellular potassium 
levels when ATP binds to the P2X7 receptor, induce these protein complexes 
to oligomerize and bring procaspase-1 into close proximity, resulting in 
autocatalytic activation of caspase-1 (Goldbach-Mansky et al., 2006). The 
active caspase-1 then acts as an intracellular cysteine protease and cleaves pro-
IL-1β in the cytosol or specialized secretory lysosomes, thereby generating an 
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active mature form of IL-1β (Figure 1.4). Besides IL-1β, caspase-1 also 
regulates the secretion of several other pro-inflammatory cytokines such as IL-
18 via the non-conventional protein secretory pathway (Keller et al., 2008). 
Since cells normally express caspase-1 as an inactive zymogen, this provides 
an additional mechanism of control for the maturation of certain pro-
inflammatory cytokines. Reduced secretion of IL-1β has been associated with 
a decrease in steady-state caspase-1 gene expression, suggesting that IL-1 can 
also regulate the synthesis of caspase-1 (Goldbach-Mansky et al., 2006). 
Human cancers such as melanoma cells with high metastatic potential are 
found to express caspase-1 in an active state, leading to the dysfunctional 
regulation of IL-1β release (Okamoto et al., 2010). 
IL-1α is cleaved by cysteine protease calpain, however, cleavage of IL-
1α is not necessary to render it biologically active as IL-1α precursor can 
induce inflammatory responses when it binds to IL-1R1. Like IL-1α, IL-1F5, 
IL-1F6, IL-1F8, IL-1F9 and IL-33 are also biologically active as full-length 
molecules. For instance, IL-33 binds to the receptor in its precursor form and 
triggers downstream signaling, whereas proteolytic cleavage by caspase-1 or 
caspase-3 actually inactivates IL-33 (Cayrol and Girard, 2009). 
 
1.4.2.2 Inhibitory IL-1 family members 
The IL-1 family consists of endogenous antagonists that competitively inhibit 
the agonists from binding to their corresponding receptors (Sims and Smith, 
2010). For instance, IL-1Ra is an endogenous inhibitor of IL-1, and it 
competes with both IL-1α and IL-1β for binding to IL-1R1. Unlike IL-1α and 
IL-1β, binding of IL-1Ra to IL-1R1 does induce the necessary conformational 
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changes for IL-1RAcP recruitment (Greenfeder et al., 1995). Since IL-1R1 
needs to associate with IL-1RacP in order to form a signaling platform to 
recruit adaptor proteins such as MyD88, IL-1Ra therefore does not induce any 
downstream signaling when it binds to IL-1R1 (Figure 1.3). 
IL-1Ra is the only gene in the IL-1 family, which encodes a signal 
peptide for its secretion via the classical endoplasmic reticulum membrane 
(ER)-Golgi secretory pathway. IL-1Ra is inducible by IL-1 signaling (Arend 
et al., 1998), and its expression triggers a negative feedback loop that regulates 
IL-1-induced responses. In addition, IL-1Ra expression is also induced by 
other pro-inflammatory stimuli such as lipopolysaccharide (LPS) or IgG 
complexes that induce IL-1 expression (Arend et al., 1998). Intracellular 
isoforms of IL-1Ra are found to be released by dying cells and like the 
secreted IL-1Ra isoform, icIL-1Ra can bind to IL-1R1 and block IL-1 
signaling (Levine et al., 1997). Given the potency of IL-1 signaling, it was 
speculated that IL-1Ra is constitutively expressed at higher levels than IL-1 in 
order to prevent excessive IL-1 signals in healthy individuals. Indeed, studies 
have shown that 100 – 300 ng/ml of endogenous IL-1Ra is found in the blood 
circulation of healthy human subjects, and it is likely that these levels are 
sufficient in limiting the effects of IL-1, which is generally present at 
picogram per milliliter range (Dinarello, 2011). The role of IL-1Ra in 
controlling IL-1-mediated inflammatory responses is demonstrated in rabbits, 
which were more susceptible to colitis when immunized against their 
endogenous IL-1Ra protein (Ferretti et al., 1994). In addition, ablation of IL-
1Ra in the mice resulted in them developing spontaneous autoinflammatory 
diseases, such as destructive arthritis (Horai et al., 2000).  
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Besides inhibition by endogenous antagonists, some pro-
inflammmatory IL-1 family members are also inhibited by binding proteins or 
by soluble receptors that are being shed by the cells. In particular, IL-1α and 
IL-1β can bind to the decoy receptor IL-1R2, which does not transduce any 
IL-1 signal. Moreover, binding of IL-1α or IL-1β to IL-1R2 leads to the 
recruitment of IL-1RacP. IL-1RacP is therefore sequestered to prevent 
excessive autocrine IL-1-mediated signaling. Although IL-1R2 too binds to 
IL-1Ra, the binding affinity between the two is lower as compared to that for 
IL-1α and IL-1β. Soluble IL-1R2 has been found in the systemic circulation 
and is proposed to act as “buffers” by binding to IL-1. 
Other mechanisms are also in place to limit the pro-inflammatory 
effects of IL-1 family members. For example, IL-18 is inhibited by IL-18BP, 
an endogenous inhibitor of IL-18 activity. Moreover, cells are found to shed 
soluble ST2 to abrogate IL-33 effects. Indeed, patients with inflammatory 
diseases have increased levels of soluble ST2 in the blood circulation, and 
exogenous administration of ST2 reduced inflammation by neutralizing the 
effects of IL-33 (Leung et al., 2004). IL-36Ra, an analogue of IL-1Ra 
regulates the biological activities of IL-36α, IL-36β and IL-36γ by binding to 
IL-1Rrp2 without recruiting IL-1RAcP, and IL-37, unlike the other agonistic 
IL-1 family members, exerts primarily anti-inflammatory effects by binding to 
IL-18R. The regulatory effects of IL-37 on the other IL-1 family members 
however, are not well understood. 
 
1.4.3 The role of IL-1 in innate and adaptive immune responses  
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IL-1 family members mediate the activation of the innate immune system, 
which in turn produce pro-inflammatory cytokines that maintain and amplify 
the initial signals. Neutrophils, monocytes and macrophages are the main 
producers of IL-1, and are able to respond to IL-1, IL-18 and IL-33 (Dinarello, 
1996; Dinarello, 2009; Gabay and McInnes, 2009; Smith, 2010). Certain 
subsets of dendritic cells (DCs) also produce IL-1, and they respond to IL-1 in 
conjunction with other cytokines by upregulating the expression of co-
stimulatory molecules such as CD40, OX40L, signaling lymphocytic 
activation molecule (SLAM) and IL-12 (Sims and Smith, 2010) (Figure 1.5).  
Earlier studies have shown that IL-1 helps in promoting and 
amplifying T cell responses. IL-1 has been initially suggested to act as a T cell 
growth factor and it is subsequently discovered that IL-1 activates Th1 and 
Th2 cells (Williams et al., 1991). IL-1 released by antigen-presenting cells 
acts on both naïve and memory T cells and influences their cellular survival 
and expansion (Ben-Sasson et al., 2009). T cells proliferate and upregulate IL-
2R expression in response to IL-1. For instance, Th2 cells express IL-1R1 and 
proliferate in the presence of IL-1 (Lichtman et al., 1988). IL-1 also plays a 
role in Th1 cell development by decreasing the expression of IL-12R by these 
cells and by regulating IL-6 dependent phosphorylation of signal transducer 
and activator of transcription 1 (STAT1) (Meng et al., 2009; Shen et al., 
2000). In addition, IL-1 activates several anti-apoptotic signaling pathways 
such as NF-κB and phosphoinositide-3-kinase pathways in the T cells, 
therefore promoting T cell proliferation and survival (O'Neill, 2008). This 
results in enhanced and prolonged primary and secondary T cell responses 
(Th2 and Th17 cells), which in turn augments B cell antibody production 
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(Ben-Sasson et al., 2009). The effect of IL-1 on promoting T cell proliferation 
is also demonstrated in effector T cells, which were able to overcome the 
inhibitory effects of regulatory T cells (Treg) in the presence of IL-1 
(O'Sullivan et al., 2006). While IL-1 amplifies T cell responses, it does not 
have much effect on Th2 cytokine secretion (Lichtman et al., 1988) (Figure 
1.5).  
Recently, the role of IL-1 in Th17 cell development and in maintaining 
Th17 cell responses has been elucidated. IL-1 is necessary for the 
differentiation of Th17 cells from naïve T cell precursors in vitro (Acosta-
Rodriguez et al., 2007; Chung et al., 2009; Kryczek et al., 2007a; Wilson et 
al., 2007), in maintaining Th17 phenotype and in promoting recall responses 
in IL-17 and IL-22-producing memory T cells (Figure 1.5). Blockade of IL-1 
inhibits the development of Th17 cell, and Il-1r1-/- mice immunized with 
protein antigens are found to have impaired Th17 cell responses (Chung et al., 
2009; Kryczek et al., 2007b). In inflamed tissues, IL-1, IL-18 and IL-33 work 
with other cytokines to induce the effector functions of memory T cells in the 
absence of a specific antigen (Guo et al., 2009). On the other hand, B cell 
proliferation is strongly induced by IL-1 in the presence of a mitogen 
(Maliszewski et al., 1990; Rousset et al., 1991). In addition, IL-1 regulates the 
expression of costimulatory molecules CD40L and OX40 on T cells, which 
are essential for B cell proliferation and class switching (Ohshima et al., 1997) 
(Figure 1.5). The importance of IL-1 in B cell antibody production is 
demonstrated in Il-1β-/- mice as these mice have significantly impaired T-cell 
dependent antibody responses (Nakae et al., 2001; Schmitz et al., 2003). 
Given its ability in activating innate immune cells as well as in promoting B 
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and T cell development and responses, IL-1 therefore plays a critical role in 
linking innate immune responses to adaptive immune response activation. 
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Adapted and modified from Nature Reviews Immunology 10, 89 – 102 (2010) 
 
Figure 1.5: The effects of interleukin-1 on immune cells. The common 
sources of IL-1 is as indicated. It is known that B and T cells produce IL-1 but 
not other members of the IL-1 family. Besides promoting naïve T cell 
proliferation and survival, IL-1 is also important for Th17 cell development. B 
cell proliferation is strongly induced by IL-1 in the presence of a mitogen. In 
addition, IL-1 regulates the expression of costimulatory molecules CD40L and 
OX40 on T cells, which are essential for B cell proliferation and class 
switching. IL-1 acts on both innate and adaptive immune cells, thus playing a 
critical role in linking innate immune responses to adaptive immune response 
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1.4.4 The role of IL-1 in tumorigenesis 
Animal studies for the past 20 years have suggested that IL-1 contributes to 
cancer progression. For instance, IL-1 is shown to be important for tumor cell 
adherence to the endothelium in vitro, and mice injected with IL-1 have 
increase in the number of metastatic tumors as well as larger tumor growth. In 
addition, Il-1ra-/- mice were most susceptible to skin carcinogenesis after 
being exposed to 3-methylcholanthrene-induced carcinogensis, as compared to 
the wild-type mice (Krelin et al., 2007). Moreover, cancer cell lines 
established from tumors from Il-1ra-/- mice were more aggressive and had 
higher metastatic potential than the wild-type mice. In contrast, some but not 
all IL-1β-/- mice developed tumors as compared to the wild-type mice, 
whereas tumor incidence in IL-1α-/- mice was similar to the wild-type mice. In 
humans, a single nucleotide polymorphism rs4251961 C allele has been 
associated with impaired production of IL-1Ra, and is commonly associated in 
type 2 diabetes (Dinarello, 2010; Larsen et al., 2009). Patients with colon 
carcinoma are associated with reduced survival if they possess this allele as 
compared to those carrying the wild-type allele.  
 
1.5 TLR family 
The Drosophila protein Toll was first shown to play a role in determining the 
dorsoventral polarity of fruit fly during embryogenesis. In addition, these 
findings demonstrated that several stretches of amino acids on the cytosolic 
signaling domain of the Toll protein are highly homologous to IL-1R1 (Gay 
and Keith, 1991), with the exception that it possesses leucine-rich repeats 
(LRRs) instead of Ig domains in the extracellular domain. Toll regulates a 
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protein kinase known as pelle, which in turn, contributes to activation of 
Dorsal, a transcription factor (Belvin and Anderson, 1996). Toll was 
subsequently found to signal via a similar pathway as IL-1 in regulating the 
expression of several target genes.  Downstream substrates of Toll signaling 
pathway includes pelle, which is homologous to IRAK while Dorsal is a 
family member of NF-κB. It was then reported in 1994 that N protein in 
tobacco is homologous to Toll protein (Whitham et al., 1994). N protein plays 
a role in conferring resistance to the tobacco mosaic virus, and it also contains 
a TIR domain like IL-1R1 and Toll (O'Neill and Greene, 1998). 
The role of Toll in inflammation and immunity only came about in 
1995 when the role of Toll protein in combating diseases like fungal 
pathogens in Drosophila was discovered (Lemaitre et al., 1996). This led to 
search for human TLRs. TLRs and IL-1 family of receptors was subsequently 
known as the IL-1R/TLR superfamily. So far ten TLRs have been identified in 
humans while mice are shown to possess 12 types of TLRs (Blander and 
Sander, 2012). The receptors of this superfamily are widely conserved in 
plants and several other species such as humans, suggesting that they are 
important in promoting host survival and evolution. TLRs are evolutionarily 
conserved pattern recognition receptors (PRRs) that recognize conserved 
pathogen-associated molecular patterns of microbial origin (Janeway and 
Medzhitov, 2002). Binding of TLRs to their specific ligands leads to the 
activation of innate immunity. TLRs can also trigger the adaptive immune 
response by activating DCs (Iwasaki and Medzhitov, 2004). 
The cellular localization of the TLRs corresponds to the 
macromolecular nature of their ligands. TLR1, TLR2, TLR4, TLR5 and TLR6 
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are expressed on the plasma membrane where they recognize lipid and protein 
ligands, whereas TLR3, TLR7, TLR8 and TLR9 are endosomal and can bind 
to nucleic acid-based ligands via their LRR domains (Sioud, 2006) (Figure 
1.6). TLR ligands arise exogenously (microbial) or endogenously (host-
derived). For instance, TLR4 binds to LPS derived from Gram-negative 
bacteria whereas TLR1, TLR2 and TLR6 recognise bacterial lipoproteins, 
bacterial lipotechoic acid and fungal zymosan. In contrast, TLR5 and TLR11 
are activated when they bind to bacterial flagellin and profiling-like molecule 
from Toxoplasma gondii respectively. TLR9 is stimulated by CpG motifs on 
DNA, while double stranded RNA is detected by TLR3. Single stranded RNA 
instead triggers TLR7 and TLR8 (Rakoff-Nahoum and Medzhitov, 2009). 
Interestingly, evolutionary development of TLR2 results in its acquired ability 
to form heterodimers with TLR1 or TLR6, thereby expanding the repertoire of 
bacterial lipopeptide ligands that the innate immune system can recognize and 
respond to (Farhat et al., 2008; Ozinsky et al., 2000). 
Despite having some subtle differences, TLRs share a conserved TIR 
domain as IL-1R1 and they signal via similar pathways. Moreover, binding of 
IL-1 to IL-1R1 induces MyD88 recruitment to the TIR domain of TLR2, 
suggesting a crosstalk between IL-1 and TLR signaling. Besides MyD88, 
TLRs also transduce signals via other adaptor proteins including TICAM1 
(also known as TRIF), TICAM2 (also known as TRAM or TIRP) and TIRAP 
(also known as MAL). When stimulated, the adaptor protein is recruited to the 
cytosolic domains of these TLRs and triggers downstream signaling events 
that lead to the activation of NF-κB, p38 and extracellular signal-regulated 
kinases (ERKs), JUN N-terminal kinases, mitogen-activated protein kinases 
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(MAPKs), and interferon regulatory factor 3 (IRF3), IRF5, and IRF7 (Lee and 
Kim, 2007) (Figure 1.6). TLR9 is pre-assembled as a dimer, of which binding 
of its ligand CpG DNA brings this complex into close association and the two 
TIR domains into juxtaposition (Latz et al., 2007).  
TLR signaling induces expression of several IL-1 family members, 
such as pro-IL-1β, IL-18 and IL-33 (Carriere et al., 2007; Okamura et al., 
1998; Schmitz et al., 2005). For instance, binding of LPS to its receptor TLR4 
leads to NF-κB activation, which then triggers the expression and synthesis of 
pro-IL-1β. This event provides the first stimulus for IL-1β production whereas 
the proteolytic maturation and secretion of IL-1β by the inflammasome and 
caspase-1 constitute the second stimulus (Mariathasan and Monack, 2007). 
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Adapted from Nature Reviews Cancer 9, 57 – 63 (2009)     
 
Figure 1.6: TLR family. TLRs recognise molecular patterns derived 
exogenously and endogenously. The cellular localization of the TLRs 
corresponds to the macromolecular nature of their ligands. Ligation of TLRs 
occurs directly or in the presence of accessory molecules such as MD2 (also 
known as LY69). This leads to the dimerisation of TLRs, followed by the 
recruitment of adaptor molecules such as MyD88 and TIR domain-containing 
adaptor inducing IFN-β (TRIF), which are important for signal transduction. 
This triggers the activation of NF-κB, MAPKs, and IRFs. TLR signaling is 
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1.5.1 TLRs and tumorigenesis 
The anti-cancer effects of TLRs were demonstrated in both mice and humans 
by local and systemic administration of the purified ligands (Garay et al., 
2007; Krieg, 2007). Injection of TLR ligands such as LPS and flagellin into 
adoptively transferred tumors resulted in tumor regression in colorectal and 
lung cancer patients in Phase II clinical trials (Chicoine et al., 2007; Otto et 
al., 1996). In addition, synthetic ligands for TLR7 and TLR8 like imiquimod 
are being tested in cancer therapies for skin cancer and chronic lymphocytic 
leukemia (Scheel et al., 2006; Spaner and Masellis, 2007; Stockfleth et al., 
2003), while TLR9 ligand CpG is considered for treatment of a number of 
human cancers and lymphoma (Carpentier et al., 2006; Krieg, 2007). It has 
been suggested that TLR ligands have potent anti-cancer effects due to their 
ability to stimulate the adaptive immune system, possibly by upregulating co-
stimulatory signals on the tumor cells. The immunomodulatory effects of TLR 
ligands are important for breaking the host tolerance to tumor self-antigens, 
and are known as adjuvanticity (Rakoff-Nahoum and Medzhitov, 2009).  
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Chapter 2: Materials and Methods 
2.1 Mice 
C57BL/6 mice were bought from the Centre for Animal Resources at the 
National University of Singapore. Il1r1-/- mice on a C57BL/6 background 
were a kind gift from Dr. Jean Pierre Abastado (Singapore Immunology 
Network, Singapore). Eµ-myc+/- mice on a C57BL/6 background were 
obtained from Jackson Laboratory (USA). Il1r1-/-, Eµ-myc+/- mice were 
generated by breeding the Il1r1-/- mice to Eµ-myc+/- mice, and F2 offsprings 
obtained from this breeding were used for all experiments. The mice were 
bred and housed in specific pathogen-free (SPF) conditions in compliance 
with the Institutional Animal Care and Use Committee guidelines at the 
National University of Singapore. 
 
2.2 Cell culture 
2.2.1 Generation and maintenance of primary murine fibroblasts 
Ears and tails of mice were harvested and cut into smaller pieces. For tissue 
dissociation and cell isolation, the pieces were incubated for 90 minutes with 
shaking at 37oC in a cocktail of RPM1 1640 medium (Invitrogen, Singapore) 
supplemented with 5 % FCS (Invitrogen, Singapore), 2.5 mg/ml of 
collagenase D (Roche, Singapore and 450 U/ml of pronase (Merck Millipore, 
Germany). The cells were then centrifuged at 1700 rpm for 7 minutes at 4 °C a 
cultured in RPMI 1640 medium (Invitrogen, Singapore) supplemented with 
5% heat inactivated FCS (Invitrogen, Singapore), 150 µM β-mercaptoethanol 
(Sigma, Singapore), 1.4 µM of L-glutamine (Sigma, Singapore), 20 U/ml of 
penicillin-streptomycin (Invitrogen, Singapore) and 20 mM of HEPES 
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(Hyclone, USA). The isolated primary fibroblasts were grown in culture for 12 
- 24 days before being used for experiments.  
2.2.2 Cell lines 
RAW 264.7 mouse monocytic leukemic macrophage cell line (ATCC, 
USA) was cultured in RPM1 1640 medium (Invitrogen, Singapore) 
supplemented with 5 % FCS (Invitrogen, Singapore). EµM2 B cell lymphoma 
cells were prepared from lymph node of 108 days old Eµ-myc transgenic 
C57BL/6 mouse as described previously (Corcoran et al., 1999) EµM2 cells 
was cultured in RPM1 1640 medium (Invitrogen, Singapore) supplemented 
with 10 % FCS (Invitrogen, Singapore). Primary fibroblasts and cell lines 
were maintained at 37 °C in a humidified 5% CO2 incubator (Thermo 
Scientific, Singapore). 
 
2.3 Plasmid constructs and transduction 
The pBABE-puro-IκBα-super repressor (IκBα-SR, Addgene plasmid 15291), 
pBABE-puro, pSicoR p53 shRNA (Addgene plasmid 12090), and pSicoR 
(Addgene plasmid 11579) plasmids were obtained from Addgene (USA) 
(Boehm et al., 2007; Ventura et al., 2004). Transduction of cells was 
performed as described before (Gasser et al., 2005). A cocktail consisting of 6 
µg of the desired plasmid, 3 µg of plasmid encoding GAG and 3 µg of plasmid 
encoding ENV was used to transfect HEK 293T cells using Transfectin 
(Biorad, Singapore). Supernatant from the transfected HEK 293T cells was 
harvested 48 hours later, passed through a 0.45 µm syringe filter (Millipore, 
USA) and added to EµM2 cells in a 6 well dish. The EµM2 cells were at about 
70 – 80 % confluency at the time of treatment. EµM2 cells were then 
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centrifuged at 2000 rpm for 90 minutes at 34°C. Selection of IκBα-SR-
expressing EµM2 cells was carried out using 5 µg/ml of puromycin (Sigma, 
Singapore) for at least 7 days prior to being used for experiments. On the other 
hand, p53 shRNA-expressing EµM2 cells selected based on their co-
expression of GFP by MoFlo XDP (Beckman Coulter Inc, USA) prior to being 
used for experiments. 
 
2.4 Treatments 
2.4.1 Treatment with chemotherapeutic drugs 
For the treatment of primary fibroblasts with bleomycin, 2.5 x 105 cells/ml 
were seeded in each well of a 6-well sterile cell culture plate the day before 
the experiment. On the day of the experiment, the cells were treated with 30 
µg/ml of bleomycin (Merck Millipore, Germany) for 20 hours, unless stated 
otherwise. Supernatant was then harvested from each well, centrifuged at 1500 
rpm for 5 minutes at 4°C to remove cell debris, and stored at -80°C until the 
next step of analysis. The treated cells were also harvested and analyzed by 
real time PCR, western blot or flow cytometry when necessary. 
To measure the kinetics for bleomycin-induced IL-1Ra mRNA 
expression and protein secretion, the cells were treated with 30 µg/ml of 
bleomycin (Merck Millipore, Germany) for the indicated time periods, and 
supernatant as well as the treated cells were harvested for analysis by ELISA 
and real time PCR respectively. 
To determine the dose effect of bleomycin on IL-1Ra secretion, the 
cells were treated with the indicated concentrations of bleomycin (Merck 
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Millipore, Germany) for 20 hours, and supernatant was harvested for ELISA 
analysis subsequently. 
For the treatment of primary fibroblasts with doxorubicin, the cells 
were treated with 0.5 µg/ml of doxorubicin (Santa Cruz technology, USA) for 
24 hours instead.  
For the treatment of RAW 264.7 cells with bleomycin, 2.5 x 105 
cells/ml were seeded in each well of a 6-well sterile cell culture plate the day 
before the experiment. On the day of the experiment, the cells were treated 
with 30 µg/ml of bleomycin (Merck Millipore, Germany) for 20 hours, unless 
stated otherwise. Supernatant was then harvested from each well, centrifuged 
at 1500 rpm for 5 minutes at 4°C to remove cell debris, and stored at -80 °C 
until the next step of analysis. 
 
2.4.2 Inhibition of de novo protein synthesis 
 Primary fibroblasts were treated with 20 µg/ml of cycloheximide 
(Merck Millipore, Germany) for 1 hour, followed by treatment with 30 µg/ml 
of bleomycin (Merck Millipore, Germany) for 20 hours. Supernatant was then 
harvested from each well, centrifuged at 1500 rpm for 5 minutes at 4 °C to 
remove cell debris, and stored at -80 °C until the next step of analysis.  
 
2.4.3 Inhibition of N-glycosylation 
 Primary fibroblasts were treated with 5 µg/ml of tunicamycin (Sigma, 
Singapore) or 20 mM of 2-Deoxy-D-glucose (Sigma, Singapore) for 1 hour, 
followed by treatment with 30 µg/ml of bleomycin (Merck Millipore, 
Germany) for 20 hours. Supernatant was then harvested from each well, 
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centrifuged at 1500 rpm for 5 minutes at 4°C to remove cell debris, and stored 
at -80 °C until the next step of analysis. 
 
2.4.4 Inhibition of classical protein secretion 
 Primary fibroblasts were treated with 30 µg/ml of bleomycin (Merck 
Millipore, Germany) for 12 hours, followed by 1 µg/ml of BD GolgiStop (BD 
Biosciences, USA) and 2 µM of Protein Transport Inhibitor (BD Biosciences, 
USA) for 6 hours. Supernatant was then harvested from each well, centrifuged 
at 1500 rpm for 5 minutes at 4°C to remove cell debris, and stored at -80 °C 
until the next step of analysis. 
 
2.4.5 Inhibition of IL-1 signaling 
Primary fibroblasts were treated with 2 µg/ml of anti-mouse IL-1α 
antibody or anti-mouse IL-1 β antibody (eBioscience, USA) for 1 hour, 
followed by treatment with 30 µg/ml of bleomycin (Merck Millipore, 
Germany) for 20 hours. Supernatant was then harvested from each well, 
centrifuged at 1500 rpm for 5 minutes at 4°C to remove cell debris, and stored 
at -80 °C until the next step of analysis. 
 
2.4.6 Inhibition of ATM and/or ATR kinases 
Primary fibroblasts were treated with 10 µM of ATM kinase-specific 
inhibitor, KU-60019 (R&D systems, USA) or 5 mM of caffeine (Sigma, 
Singapore) for 1 hour, followed by treatment with 30 µg/ml of bleomycin 
(Merck Millipore, Germany) for 20 hours. Supernatant was then harvested 
from each well, centrifuged at 1500 rpm for 5 minutes at 4°C to remove cell 
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debris, and stored at -80°C until the next step of analysis. The treated cells 
were also harvested and analyzed by flow cytometry. 
2.4.7 Inhibition of caspase activation 
For general caspases inhibition, primary fibroblasts were treated with 
20 µM of general caspase inhibitor, Z-VAD-FMK (Santa Cruz technology, 
USA) for 1 hour, followed by treatment with 30 µg/ml of bleomycin (Merck 
Millipore, Germany) for 20 hours. Supernatant was then harvested from each 
well, centrifuged at 1500 rpm for 5 minutes at 4°C to remove cell debris, and 
stored at -80°C until the next step of analysis. The treated cells were also 
harvested and analyzed by flow cytometry. 
For inhibition of caspase-9 and caspase-3, primary fibroblasts were 
treated with 10 µM of caspase-9 inhibitor, Z-LEHD-FMK (BD Biosciences, 
USA) or 10 µM of caspase-3 inhibitor, Z-DEVD-FMK (Santa Cruz 
technology, USA) for 1 hour, followed by treatment with 30 µg/ml of 
bleomycin (Merck Millipore, Germany) for 14 hours. Supernatant was then 
harvested from each well, centrifuged at 1500 rpm for 5 minutes at 4°C to 
remove cell debris, and stored at -80°C until the next step of analysis. 
2.4.8 IL-1Ra bioactivity assay 
2.5 x 105 cells/ml were seeded in each well of a 6-well sterile cell 
culture plate the day before the experiment. On the day of the experiment, the 
cells were treated with 30 µg/ml of bleomycin (Merck Millipore, Germany) 
for 24 hours. Meanwhile, a second set of fibroblasts was prepared by seeding 
2.5 x 105 cells/ml in each well of a 6-well sterile cell culture plate. Supernatant 
was harvested from the first set of fibroblasts that was treated with bleomycin 
the very next day, centrifuged at 1500 rpm for 5 minutes at 4°C to remove cell 
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debris, and transferred to the second set of fibroblasts. The second set of 
fibroblasts was incubated with the supernatant for 1 hour, followed by 
treatment with recombinant IL-1α (Peprotech, USA) at the indicated 
concentrations for 6 hours. The treated cells were then harvested and analyzed 
by real time PCR. 
 
2.4.9 Treatment of EµM2 cells 
EµM2 cells were seeded 4 hours before the experiment at a density of 1 x 105 
cells/ml per 25 cm2 sterile cell culture. The cells were then treated with 0.1 % 
of endotoxin-free water (Invivogen, USA) or 1 µg/ml of Pam3CSK4 for 24 
hours (Invivogen, USA), followed by 0.01 % DMSO or 1 µM of Ara-C 
(Sigma, Singapore) for 16 hours. The treated cells were then harvested and 
analyzed by western blot or flow cytometry. 
 
2.5 Quantitative real time PCR 
RNeasy Mini kit (Qiagen, Singapore) was used to isolate total RNA from 
treated cells. Reverse transcription was then performed using 2 µg of total 
RNA, random hexamer primer and moloney murine leukemia virus reverse 
transcriptase (M-MLV RT; Promega, Singapore). For PCR, amplification 
mixture consisting of 50 ng of reverse transcribed RNA, 0.2 µM forward 
primer, 0.2 µM reverse primer and 12.5 µl of iTaq SYBR Green Supermix 
with ROX (Biorad Laboratories, Singapore) was then prepared (25 µl). PCRs 
were performed in duplicates using the ABI PRISM 7700 Sequence Detection 
System from Applied Biosystems, and the PCR thermocycling parameters 
were 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 
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sec and 60°C for 15 sec and 72°C for 1 minute. All samples were normalized 
to their respective housekeeping gene hypoxanthine phosphoribosyltransferase 
(HPRT). The following primers were used: HPRT-5’, tgggaggccatcacattgt, 
HPRT-3’: gcttttccagtttcactaatgaca; IL-1α-5’: gccagttgagtaggataaagg, IL-1α-3’: 
cagtctgtctccttcttgagg; IL-1β-5’: tcacagcagcacatcaacaa, IL-1β-3’: 
tgtcctcatcctggaaggtc; total IL-1Ra-5’: gggatactaaccagaagacc, total IL-1Ra-3’: 
gacaggcacagcttgccccc; sIL-1Ra-5’: cttgctgtggcctcgggatgg, sIL-1Ra-3’: 
cttttcccagaagggcggcagg; icIL-1Ra-5’:  tccaccctgggaaggtctgtgc, icIL-1Ra-3’:  
gctgcctctgaagccatgggtg. Samples without RNA were included as negative 
controls, and the results were analyzed using GraphPad Prism software 
(GraphPad Software, USA). 
 
2.6 Antibody staining of cells for flow cytometry 
2.6.1 Antibody staining of primary fibroblasts and cell lines 
Primary murine fibroblasts were treated as required, harvested and centrifuged 
at 1500 rpm at 4oC for 5 minutes, before incubation with the following 
antibodies: anti-intercellular adhesion molecule-1 (ICAM)-1-FITC 
(eBioscience, USA) or anti-IL-1R1-PE (BD Pharmingen, USA) at 4oC for 30 
minutes. EµM2 cells were treated as required, harvested and incubated with 
the following antibodies: anti-CD69-FITC, anti-CD80-PE, anti-CD86-APC, 
anti-H-2Kb-PE or anti-ICAM-1-FITC (eBioscience, USA).  
Data acquisition was carried out using a FACSCalibur flow cytometer 
(BD Biosciences, USA), and results were analyzed using Flowjo software 
(Tree Star Inc, USA). Dead cells were excluded from the analysis based on the 
side scatter vs forward scatter profile, and based on the PI fluorescence signal. 
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2.6.2 Antibody staining of primary blood lymphocytes 
Primary lymphocytes harvested from the blood were first incubated with 
CD16/32 antibodies (eBioscience, USA) at 4°C for 10 - 15 minutes so as to 
block the Fc receptors, followed by staining with the following antibodies: 
anti-B220-APC, anti-NK1.1-FITC, anti-CD3-Percp-Cy5.5, anti-CD4-PE-Cy7, 
anti-CD8a-PB and anti-IL-1R1-PE (eBioscience,USA) at 4oC for 30 minutes. 
Data acquisition was carried out using a LSRFortessa flow cytometer (BD 
Biosciences, USA), and results were analyzed using Flowjo software (Tree 
Star Inc, USA). 
 
2.7 Intracellular staining of caspase 3 
Intracellular staining of caspase-3 was performed using the BD intracellular 
fixation and permeabilization kit (BD Biosciences, USA), according to the 
manufacturer’s instructions. Briefly, cells were first stained with Fixable 
Viability Dye eFluor 780 (eBioscience, USA) at 4°C for 30 minutes. Data 
acquisition was carried out using CyAn ADP analyzer (Beckman Coulter, 
Singapore) and analyzed using Flowjo software (Tree Star Inc, USA). 
 
2.8 Analysis of cell cycle distribution 
Cells were first harvested and fixed by adding 70 % ice-cold ethanol dropwise, 
and were incubated at 4oC for at least half an hour. The cells were then 
pelleted by centrifugation at 1500 rpm for 5 minutes at 4°C and stained with 
50 µg/ml of PI (Sigma, Singapore) and 10 µg/ml of RNase A (Sigma, 
Singapore). Subsequently, 2 x 104 events were acquired per sample and total 
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cellular DNA content in the cells was analyzed using FACSCalibur flow 
cytometer (BD Biosciences, USA) and Flowjo software (Tree Star Inc, USA). 
Cell aggregates or doublets were excluded from analysis based on the width of 
PI fluorescence signal. 
 
2.9 Analysis of apoptosis 
Detection of apoptotic cells was carried out using Annexin V apoptosis 
detection kit (eBioscience, USA) according to manufacturer’s guidelines. 
Briefly, cells were treated as required and were pelleted by centrifugation at 
1500 rpm for 5 minutes at 4 °C. The cells were washed once with PBS, 
followed by binding buffer, and incubated with APC-conjugated Annexin V 
(eBioscience, USA) at room temperature for 15 minutes. 7-AAD 
(eBioscience, USA) was added to the samples prior to flow cytometry. 2 x 104 
events were acquired per sample using CyAn ADP analyzer (Beckman 
Coulter, Singapore) and analyzed using Flowjo software (Tree Star Inc, USA). 
 
2.10 Analysis of mitochondrial membrane potential 
Measurement of mitochondrial membrane potential was carried out using 
MitoProbe JC-1 assay kit for flow cytometry (Invitrogen, Singapore) 
according to manufacturer’s guidelines. Briefly, cells were treated as required 
and were pelleted by centrifugation at 1500 rpm for 5 minutes at 4°C. The 
cells were resuspended with PBS and incubated with 2 µM 5,5’,6,6’-
tetrachloro-1,1’,3,3’-tetraethylbenzimidazolcarbocyanine iodide (JC-1) 
(Invitrogen, Singapore) at 37°C for 30 minutes. Data acquisition was carried 
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out using a CyAn ADP analyzer (Beckman Coulter, Singapore), and results 
were analyzed using Flowjo software (Tree Star Inc, USA).  
 
2.11 Western Blotting 
For the preparation of whole-cell extracts, cells were lysed in Radio-
Immunoprecipitation Assay (RIPA) buffer consisting of 150 mM NaCl, 1 mM 
EDTA, 50 mM Tris-HCl (pH 7.4), 1% NP-40 and 1% sodium deoxycholate 
(Sigma, Singapore). In addition, protease inhibitor cocktail set III and 
phosphatase inhibitor cocktail set V (Merck Millipore, Germany) were added 
to the lysis buffer according to the manufacturer’s instructions prior to cell 
lysis. The whole-cell extracts were then electrophoresed in 10%, 12%, or 15% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis gels, and blotted 
onto nitrocellulose membranes. For experiments involving the use of primary 
murine fibroblasts, the following antibodies were used: phospho–H2AX-
Ser139 (γH2AX), phospho–p53-Ser18 (p-p53), p53 (Cell Signaling 
Technology, USA), p21 (WAF1/CIP1) (Santa Cruz Biotechnology, USA), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Sigma, Singapore). For 
experiments involving the use of EµM2 cells, the following antibodies were 
used: γH2AX, p-p53, p53, IκBα, phospho-IκB kinase α/β (p-IKK α/β), IKKα 
and IKKβ, phospho-p65 (p-p65) and p65 (Cell Signaling Technology, USA), 
p21 (WAF1/CIP1) (Santa Cruz Biotechnology, USA), GAPDH (Sigma, 
Singapore). Horseradish peroxidase–coupled second-stage reagents were used 
to develop the blots (Thermo, Singapore). Blots were exposed on x-ray film 
(Fuji, Singapore). Protein bands were quantitated using ImageJ software 
(National Institutes of Health, Bethesda, MD) based on measurement of 
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relative intensity. Values were further normalized to GAPDH levels of 
respective blots. 
 
2.12 Cytokine ELISAs 
The quantification of IL-1α and IL-1Ra was determined using ELISA kits 
(R&D systems, USA), and quantification of IL-1β and IL-6 was determined 




2.13.1 Deparaffinisation and rehydration of tissue sections 
Intestinal tissue sections (5 µm thick) were a kind gift from Dr. K Lenhard 
Rudolph (University of Ulm, Germany) (Rudolph et al., 1999). The sections 
were first deparaffinised by immersing them in two changes of xylene for 3 
minutes each, followed by two changes of 100 % ethanol for 3 minutes each, 
95 % ethanol for 3 minutes, 70 % ethanol for 3 minutes and 50 % ethanol for 
3 minutes. The sections were then kept in PBS until the next step. 
 
2.13.2 Antigen retrieval and staining 
The rehydrated tissue sections were boiled in citrate buffer (10mM Sodium 
Citrate, 0.05% Tween 20, pH 6.0) for 3 minutes using a pressure cooker. The 
sections were then washed in two changes of TBS plus Triton X-100 (0.025 
%) followed by blocking with TBS plus donkey serum (10 %).  Subsequently, 
tissue sections were incubated with anti-IL-1Ra antibody (R&D systems, 
USA) overnight at 4°C in humidified chamber, then with Cy3-conjugated 
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donkey anti-goat IgG for 1 hour at room temperature. These slides were 
mounted using DAPI containing Vectashield mounting medium (Vector 
Laboratories, USA), and data was acquired and processed using Zeiss 
fluorescence microscope (Carl Zeiss, Germany) and Photoshop CS5 (Adobe, 
USA). 
 
2.14 Caspase assays 
Caspase-Glo assays (Promega, Madison, WI) were used to measure caspase-
3/7, -8, -9 activities. The assays were carried out as described in the 
manufacturer’s cell based assay protocol. To summarise, 20,000 – 40,000 of 
primary murine fibroblasts were grown per well in a 96-well white-walled cell 
culture plate in triplicates and treated at various times as indicated. Prior to 
analysis, 0.1 ml of Caspase-Glo assay reagent (including the MG-132 inhibitor 
for Caspase-Glo 8 and 9 assays) was added to each well and the plates were 
incubated at room temperature for 1 hour at room temperature. Luminescent 
signals were then collected using a Wallac 1420 VICTOR2 (Perkin Elmer, 
USA). 
 
2.15 Analysis of tumor progression in IL-1R1 x Eµ-myc+/- mice 
2.15.1 Tumor load determination 
Blood was collected from mice by facial bleeding. Red blood cells were 
subsequently removed from the blood samples by performing red blood cells 
lysis prior to staining with antibodies. Cells in the blood were first treated with 
CD16/CD32 specific antibodies at 4°C for 10 minutes, followed by incubation 
with the following antibodies: anti-B220-APC and anti-IgM-FITC 
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(eBioscience, USA) at 4°C for 30 minutes. Data acquisition was carried out 
using a FACSCalibur flow cytometer (BD Biosciences, USA), and results 
were analyzed using Flowjo software (Tree Star Inc, USA). Tumor load refers 
to the B220low cell population, which is calculated as follows: Σ 
%B220lowIgM- x %B220+ + B220lowIgM+ x %B220+. 
 
2.15.2 Survival analysis 
Survival of Il1r1+/+, Eµ-myc+/- and Il1r1-/-, Eµ-myc+/- mice was monitored over 
a time period of 300 days. Survival was represented by Kaplan-Meier curves 
and survival was analysed using the statistical analysis tool log rank Mantel-
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Chapter 3: Genotoxic stress activates DDR and induces secretion of IL-1Ra, 
but suppresses IL-1Ra mRNA steady state levels 
Several studies have shown that persistent and unresolved DNA breaks can 
induce cells to be permanently arrested in the cell cycle. These cells 
subsequently express a complex phenotype known as SASP by upregulating 
several pro-inflammatory factors (Coppe et al., 2008; Rodier et al., 2009; Yu 
et al., 2013). Factors released by these cells can potentially modulate the tissue 
microenvironment, and even activate and recruit immune cells that in turn 
recognize and attack the senescent cells (Lujambio et al., 2013; Xue et al., 
2007). The ability of damaged cells to modulate inflammation as an initial and 
immediate response to genotoxic stress is however, not well understood. Past 
findings have shown that IL-1 is the critical inducer for initiating a 
senescence-associated phenotype, as well as for reinforcing the state of 
permanent cell cycle arrest (Acosta et al., 2013; Orjalo et al., 2009). 
Moreover, our initial analyses based the microarray data derived from mice 
with functional or dysfunctional telomeres (Begus-Nahrmann et al., 2009) 
suggested that the receptor for IL-1 signaling (IL-1R1) might be regulated by 
genotoxic stress (data not shown). With these data in mind, we therefore set 
out to study the effects of genotoxic stress on the regulation of IL-1 family 
members in the early phase of DNA damage response.  
 
3.1 Bleomycin induces DDR and apoptosis 
Bleomycin is a radiomimetic chemotherapy drug that is being used in clinics 
for treatment of several human cancers. It induces genotoxic stress in cancer 
cells by causing single strand and double strand DNA breaks, leading to 
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activation of DDR, cell cycle arrest and even cell death by apoptosis. To 
generate an in vitro system, which is able to respond appropriately to 
genotoxic stress as well as to modulate inflammatory responses by producing 
cytokines, we therefore performed our studies using primary murine 
fibroblasts. We treated primary murine fibroblasts with bleomycin (bleo) and 
observed that γH2AX, which mediates DDR signaling, is upregulated in 
response to the treatment (Figure 3.1a). Previous studies have shown that 
effector proteins such as p53 are phosphorylated in response to DDR, which in 
turn activate transcription of genes that inhibit cell-cycle progression and 
induce DNA repair systems (Bunz et al., 1998; Chan et al., 1999). Indeed, we 
observed an increase in p53 phosphorylation at serine residue 18, a response to 
activate p53 effector functions during DNA damage (Dumaz and Meek, 1999; 
Fiscella et al., 1993; Mayr et al., 1995). Despite p21 being a transcriptional 
target of p53 however (Di Leonardo et al., 1994; el-Deiry et al., 1994; Xiong 
et al., 1993), there was no obvious difference in p21 protein levels between 
murine fibroblasts that were treated with vehicle (veh) or bleomycin. We 
therefore investigated the effects of p53 activation on the protein expression of 
another known p53 target gene, ICAM-1 (Gorgoulis et al., 2003). We 
observed that ICAM-1 cell surface expression was upregulated in response to 
bleomycin treatment (Figure 3.1b). In contrast, the upregulation of ICAM-1 
was prevented in cells that were deficient for p53 (data not shown). This 
suggests that bleomycin activates DDR, which in turn induces the effector 
functions of p53.  
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Figure 3.1: Bleomycin activates DDR pathway in murine primary 
fibroblasts. (A) Cell extracts from murine fibroblasts treated with vehicle or 
bleomycin (30 µg/ml) were analyzed for levels of H2AX phosphorylated at 
serine residue 139 (γH2AX), p53 phosphorylated at serine residue 18 (p-p53), 
total p53 and p21 by immunoblotting. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was included as a loading control. Experiment was 
reproduced three times. (B) Murine fibroblasts treated with vehicle or 
bleomycin (30 µg/ml) were assessed for surface expression levels of 
intercellular adhesion molecule-1 (ICAM-1) by flow cytometry. ICAM-1 
expression by cells treated with vehicle or bleomycin (thin and thick lines 
respectively) were compared to isotype controls (filled histograms and dashed 
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Without proper repair of the DNA lesions, progression into the next 
phase of the cell cycle can be detrimental to the viability of the damaged cell 
(Bartek et al., 2004). Cells are therefore arrested in the cell cycle in response 
to genotoxic stress until the DNA breaks have been repaired. When analyzing 
for the effect of bleomycin on cell cycle by flow cytometry, we showed that 
bleomycin significantly increased the proportion of cells arrested at G2/M 
phase (Figures 3.2a & b) while the percentage of cells in the G0/G1 phase 
was reduced. This demonstrates that bleomycin induces cell cycle arrest due to 
DDR activation . 
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Figure 3.2: Bleomycin induces cell cycle arrest at G2/M phase. (A) Murine 
fibroblasts treated with vehicle or bleomycin (30 µg/ml) were analysed for 
cell-cycle distribution. Analysis of DNA content by propidium iodide (PI) 
staining was carried out using flow cytometry. (B) Results in (A) are 
quantified as percentages of cells at each stage of the cell cycle. Statistical 
comparisons were conducted using Student’s t test and the results are 
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DDR also induces cells to undergo apoptosis if the damage is too 
extensive to be repaired (Clarke et al., 1993; Lowe et al., 1993). When 
assessing for the percentage of apoptotic cells by flow cytometry, we observed 
that bleomycin induced apoptosis in a delayed manner as the percentage of 
early apoptotic cells (Annexin V+ 7-AAD-) and late apoptotic cells (Annexin 
V+ 7-AAD+) significantly increased only after 24 hours of treatment with 
bleomycin as compared to that at 0 hour (Figures 3.3a & b). The percentage 
of apoptotic cells continued to increase till 48 hours of treatment with 
bleomycin (13.6 % for Annexin V+ 7-AAD- and 12.5 % for Annexin V+ 7-
AAD+ cells).  
Cells undergoing necrosis would exhibit a much faster uptake of PI as 
compared to that for apoptotic cells due to damage incurred by the plasma 
membrane during necrosis (Vitale et al., 1993). In our system, bleomycin did 
not induce necrosis, as the percentage of 7-AAD+ cells was only significantly 
increased after 48 hours of treatment with bleomycin as compared to that at 0 
hour (18.9 % vs 7.2 %, Figures 3.4a & b). Overall, our results indicate that 
treating murine fibroblasts with bleomycin for 24 hours induces apoptosis but 
not necrosis. 
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Figure 3.3: Bleomycin induces apoptosis. (A) Murine fibroblasts treated 
with bleomycin (30 µg/ml) for the indicated time periods were assessed for 
apoptosis by staining for 7-amino-actinomycin D (7-AAD) and Annexin V. 
Annexin V+ 7-AAD- and Annexin V+ 7-AAD+ cells were considered 
apoptotic. Representative dot-plots of Annexin V/7-AAD bivariate flow 
cytometry from three independent experiments are shown. (B) Results in (A) 
were quantified as percentages of cells at each stage of apoptosis. Annexin V+ 
7-AAD- (filled squares) represents early apoptotic cells and Annexin V+ 7-
AAD+ (open circles) represents late apoptotic/necrotic cells. Statistical 
comparisons were conducted using one-way ANOVA and the results are 
expressed as means ± SE of three independent experiments. *, P < 0.05; **, P 











0 h 4 h 8 h 24 h 48 h 
B 




























	  	   66 
 
 
Figure 3.4: Bleomycin does not induce necrosis. (A) Murine fibroblasts 
treated with bleomycin (30 µg/ml) for the indicated time periods were 
assessed for necrosis by staining for 7-AAD. Representative histograms from 
three independent experiments are shown. (B) Results in (A) were quantified 
as the percentages of cells that are positive for 7-AAD. Statistical comparisons 
were conducted using one-way ANOVA and the results are expressed as 
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We next determined the effect of bleomycin on cellular apoptosis by 
titrating the dose of bleomycin. Consistent with our earlier observations, 
treatment of murine fibroblasts with bleomycin for 24 hours induced the cells 
to undergo early stages of apoptosis (Figures 3.5a & b). The proportion of 
early apoptotic cells (Annexin V+ 7-AAD-) increased significantly when 10 
µg/ml of bleomycin was used for treatment as compared to that for 0 µg/ml, 
and the percentage of Annexin V+ 7-AAD- cells reached a plateau when the 
dose of bleomycin was further increased to 30 µg/ml. In summary our data 
suggest that bleomycin activates DDR in primary murine fibroblasts and 
induces cellular apoptosis in a dose-dependent manner. 
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Figure 3.5: Effect of bleomycin on cell death is dose-dependent. (A) 
Murine fibroblasts treated with bleomycin for 24 hours at the indicated 
concentrations were assessed for apoptosis by staining for 7-AAD and 
Annexin V. Annexin V+ 7-AAD- and Annexin V+ 7-AAD+ cells were 
considered apoptotic. Representative dot-plots of Annexin V/7-AAD bivariate 
flow cytometry from three independent experiments are shown. (B) Results in 
(A) were quantified as percentages of cells at each stage of apoptosis. Annexin 
V+ 7-AAD- (filled squares) represents early apoptotic cells and Annexin V+ 7-
AAD+ (open circles) represents late apoptotic/necrotic cells. Statistical 
comparisons were conducted using one-way ANOVA and the results are 
expressed as means ± SE of three independent experiments. **, P < 0.01; ***, 
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3.2 Treatment of primary fibroblasts with bleomycin induces IL-1Ra 
secretion 
Previous studies demonstrate that unresolved DNA lesions led to persistent 
DNA damage signaling and induced cells to enter cellular senescence after 6 – 
10 days (Di Leonardo et al., 1994; Rodier et al., 2009). At the same time, the 
senescent cells upregulated expression of several pro-inflammatory genes and 
released factors that could potentially modulate their tissue microenvironment 
(Coppe et al., 2008; Rodier et al., 2009). To better understand the effect of 
genotoxic stress on signaling pathways in inflammation, we compared the 
microarray data of intestinal tissue from aging mice with dysfunctional 
telomeres with that of the littermates with functional telomeres (data not 
shown). Telomere dysfunction induces genotoxic stress and activates DNA 
damage signaling in aging mice (Begus-Nahrmann et al., 2009; Schaetzlein et 
al., 2007). Our initial analysis suggested that genotoxic stress due to 
dysfunctional telomeres, may in turn regulate the expression of IL-1 family. 
To confirm our findings from the preliminary analysis, we first investigated 
the effect of bleomycin on IL-1α, IL-1β, IL-1R1 and IL-1Ra mRNA steady 
state levels. Treatment with bleomycin did not have any significant effect on 
IL-1α mRNA steady state levels (Figure 3.6a), but increased IL-1β levels by 
about 3-fold (Figure 3.6b). On the other hand, IL-1R1 and IL-1Ra mRNA 
steady state levels were significantly reduced in response to bleomycin (by 
4.3-fold and 5-fold respectively, Figures 3.6c & d). Bleomycin induced a 
two-fold increase in p21 mRNA steady state levels (Figure 3.6e), which is 
consistent with previous studies and with our earlier observations that 
bleomycin induces DDR and p53 activation. 
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We next validated our observations by assessing protein expression 
levels of the IL-1 family members after treatment of primary fibroblasts with 
vehicle or bleomycin. No significant difference in IL-1R1 protein expression 
levels was detected when the cells were treated with bleomycin (Figure 3.7a), 
despite IL-1R1 being down regulated at mRNA level. In contrast, IL-1Ra 
protein levels were significantly upregulated in the presence of bleomycin as 
compared to the vehicle-treated group (Figure 3.7b), suggesting that the 
changes in IL-1Ra mRNA levels and IL-1Ra protein expression levels are 
inversely correlated in response to bleomycin treatment. IL-1α and IL-1β 
protein levels on the other hand, were below the detection limits of our assays 
and we were hence unable to determine the effect of bleomycin on IL-1α and 
IL-1β protein expression. 
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Figure 3.6: Bleomycin induces IL-1β mRNA steady state level and 
suppresses IL-1R1 and IL-1Ra mRNA steady state levels. Primary mouse 
dermal fibroblasts of C57BL/6 adult mice treated with vehicle or bleomycin 
(30 µg/ml) were assessed for (A) IL-1α,  (B) IL-1β, (C) IL-1R1, (D) IL-1Ra 
and (E) p21 mRNA expression by quantitative real-time RT-PCR. The data 
for all samples were normalised to their respective hypoxanthine 
phosphoribosyltransferase (HPRT) mRNA levels, and compared to vehicle-
treated (set to 1). Statistical comparisons were conducted using Student’s t test 
and the results are expressed as means ± SE of three independent experiments. 
**, P < 0.01; ***, P < 0.001.  
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Figure 3.7: Bleomycin induces IL-1Ra secretion and has no effect on IL-
1R1 cell surface expression. (A) Murine fibroblasts treated with vehicle or 
bleomycin (30 µg/ml) were assessed for surface expression levels of IL-1R1 
by flow cytometry. IL-1R1 expression by cells treated with vehicle or 
bleomycin (thin and thick lines respectively) were compared to isotype 
controls (filled histograms and dashed lines respectively). Experiment was 
reproduced three times. (B) Supernatant from murine fibroblasts treated with 
vehicle or 30 µg/ml of bleomycin was collected after 18 - 20 hours and 
analyzed for IL-1Ra by ELISA. Statistical comparisons were conducted using 
Student’s t test and the results are expressed as means ± SE of four 
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3.3 Treatment of RAW 264.7 cells with bleomycin induces IL-1Ra 
secretion 
To extend our findings to cancer cells, we treated RAW 264.7 cells with 
vehicle or bleomycin and assessed for changes in IL-1Ra protein levels. 
Similar to our earlier observations for primary fibroblasts, bleomycin induced 
IL-1Ra in RAW 264.7 cells to secrete higher levels of IL-1Ra as compared to 
the vehicle-treated group (by 4.6-fold, Figure 3.8). This indicates that 
chemotherapy treatment induces both primary cells and cancer cell lines to 
secrete IL-1Ra. 
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Figure 3.8: RAW 264.7 macrophage cell line secretes IL-1Ra in the 
presence of bleomycin. Supernatant from RAW 264.7 macrophage cell line 
treated with vehicle or 30 µg/ml of bleomycin was collected after 18 - 20 
hours of treatment and analyzed for IL-1Ra by ELISA. The secretion levels 
were compared to vehicle-treated group (set to 1). Statistical comparisons 
were conducted using Student’s t test and the results are expressed as means ± 
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3.4 Treatment of primary fibroblasts with doxorubicin induces IL-
1Ra secretion 
To study if chemotherapy drugs other than bleomycin can induce IL-1Ra 
secretion, we repeated the experiment using doxorubicin, a classical 
topoisomerase II poison (Burden and Osheroff, 1998) to treat primary murine 
fibroblasts. Topoisomerase enzymes unwind DNA helices by generating 
cleaved DNA complex during DNA transcription or replication (Liu et al., 
1983; Tewey et al., 1984). Doxorubicin interferes with the action of 
topoisomerase enzymes by intercalating the DNA and preventing the cleaved 
duplex DNA from re-ligating, therefore generating DNA double strand breaks. 
When treated with doxorubicin, primary fibroblasts upregulated IL-1Ra 
secretion by about 2.5-fold, hence demonstrating that cells increase secretion 
of IL-1Ra in response to chemotherapy drugs (Figure 3.9). 
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Figure 3.9: Secretion of IL-1Ra by primary fibroblasts is induced by 
doxorubicin. Supernatant from murine fibroblasts treated with vehicle or 0.5 
µg/ml doxorubicin were collected after 24 hours and analyzed for IL-1Ra by 
ELISA. Statistical comparisons were conducted using Student’s t test and the 
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3.5 Telomerase-deficient intestinal epithelial cells upregulate IL-1Ra 
expression 
To extend our data in vivo, we next studied the effect of telomere dysfunction 
on IL-1Ra expression in intestinal tissue sections from late generation 
telomerase-knockout mice. Telomerases are specialized reverse transcriptases 
that play a crucial role in maintaining telomeres (Greider and Blackburn, 
1985). Loss of telomerase activity results in nucleotides not being 
appropriately replenished during the replication process, hence leading to the 
erosion of telomeric ends (Teixeira et al., 2004). This in turn causes 
inappropriate chromosome fusions and rearrangements that threaten the 
survival of a cell (Maser and DePinho, 2004). Similar to classical internal 
DNA lesions, dysfunctional telomeres activate DDR and DNA repair 
mechanisms. 
To determine the effect of telomere dysfunction on IL-1Ra expression, 
we performed immunohistochemistry staining on intestinal tissue sections of 
late generation telomerase-knockout mice. Previously, it is shown that late 
generation telomerase-knockout mice exhibited villous atrophy and zonal 
blunting, resulting in organ dysfunction and significantly shortened lifespan 
(Choudhury et al., 2007; Hemann et al., 2001; Rudolph et al., 1999; 
Schaetzlein et al., 2007). Besides upregulating DDR markers such as γH2AX, 
intestinal epithelial cells from the mutant mice also expressed significantly 
higher percentage of anaphase bridges in the intestinal crypts of late 
generation telomerase-knockout mice (Begus-Nahrmann et al., 2009; Rudolph 
et al., 1999). This suggests that telomere dysfunction causes genotoxic stress 
that in turn, results in activation of DDR. By performing 
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immunohistochemistry staining, we detected high levels of IL-1Ra protein 
expression in the intestinal crypts of the late generation telomerase-knockout 
mice (Figure 3.10). In contrast, IL-1Ra was not detected in the intestinal 
crypts of the mice that expressed functional telomerase. The detected signals 
are specific to IL-1Ra antibody stain as we did not detect any fluorescent 
signals in the control group that were only treated with secondary antibodies. 
Our results therefore indicate that loss of telomerase induces IL-1Ra secretion 
in vivo. 
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Figure 3.10: Telomere dysfunction induces IL-1Ra expression in 
telomerase-deficient intestinal epithelial cells. Representative 
immunohistochemistry against nuclei stain (blue) and control stain (secondary 
antibody only) or IL-1Ra (red) using intestinal tissue sections from late-
generation telomerase deficient mice (iG4). This is compared to intestinal 
tissue sections from mice that express telomerase (iF1). White arrows point to 
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3.6 Bleomycin-induced IL-1Ra secretion accumulates with time but is 
repressed at mRNA expression level 
To understand the kinetics of IL-1Ra regulation, we treated primary 
fibroblasts with bleomycin at various time points and assessed for the mRNA 
expression of different IL-1Ra isoforms by real time PCR. Previous studies 
have shown that Il1rn gene gives rise to two different types of splice variants 
– the secreted and the intracellular forms. In addition, the intracellular form 
consists of two subtypes, both of which do not possess a signal peptide (Gabay 
et al., 1997a; Malyak et al., 1998; Muzio et al., 1995). Our data shows that the 
changes in mRNA expression were similar for both sIL-1Ra and icIL-1Ra 
type I isoforms, where the mRNA levels decreased with increasing drug 
treatment duration (Figure 3.11). We detected a significant 2.5-fold decrease 
in mRNA expression for both isoforms after 4 hours of treatment with 
bleomycin as compared to that at 0 hour, and the levels continued to decrease 
up to 24 hours of treatment with bleomycin (by 3.6-fold for sIL-1Ra isoform 
and by 8.3-fold for icIL-1Ra type I isoform). icIL-1Ra type II isoform mRNA 
expression was detected at much lower levels as compared to that for sIL-1Ra 
and icIL-1Ra, and displayed a similar pattern of change with time as sIL-1Ra 
and icIL-1Ra (data not shown). The mRNA levels of total IL-1Ra also 
reflected the observed changes for the isoforms (Figure 3.11).  
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Figure 3.11: IL-1Ra mRNA steady state levels decrease in response to 
bleomycin treatment. Murine fibroblasts treated with bleomycin (30 µg/ml) 
for the indicated time periods were assessed for total IL-1Ra, secreted IL-1Ra 
isoform (sIL-1Ra) and intracellular IL-1Ra isoform (icIL-1Ra) mRNA 
expression by quantitative real-time RT-PCR. The data for all samples were 
normalised to their respective HPRT mRNA levels, and compared to 0 hour of 
treatment (set to 1). Statistical comparisons were conducted using one-way 
ANOVA, and the results are expressed as means ± SE of two independent 
experiments. *, P < 0.05; **, P < 0.01. 
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 We also studied the kinetics of IL-1Ra protein regulation by treating 
the primary fibroblasts with bleomycin at various time points, and 
subsequently assessing for the changes in IL-1Ra secretion by ELISA.  
Consistent with our earlier observations, the change in IL-1Ra secretion levels 
with time was inversely correlated to that observed for the mRNA steady state 
levels (Figures 3.6 & 3.7b). IL-1Ra secretion levels gradually increased with 
time after bleomycin treatment, and was significantly enhanced by 2.4-fold 
after 16 hours of treatment with bleomycin as compared to that at 0 hour 
(Figure 3.12). Although IL-1Ra mRNA levels were significantly reduced in 
response to bleomycin (Figure 3.11), the secretion levels for IL-1Ra 
continued to increase even up to 48 hours after treatment (Figure 3.13a). 
 Our results also showed that IL-1Ra secretion was dependent on the 
concentration of bleomycin. By varying the dose of bleomycin, IL-1Ra 
secretion was significantly induced when 30 µg/ml of bleomycin was used as 
compared to that for 0 µg/ml (Figure 3.13b). The secretion levels reached a 
plateau when the dose of bleomycin was further increased to 100 µg/ml. In 
summary, our data suggested that bleomycin-induced IL-1Ra secretion is 
independent of transcriptional regulation. In addition, IL-1Ra secretion is 
dependent on the duration of treatment as well as the concentration of 
bleomycin. Thereafter, all experiments were performed using 30 µg/ml of 
bleomycin, and the cells were treated for 20 to 24 hours unless indicated 
otherwise. 
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Figure 3.12: IL-1Ra secretion increases in response to bleomycin 
treatment. Supernatant from murine fibroblasts treated with bleomycin (30 
µg/ml) for the indicated time periods were collected and analyzed for IL-1Ra 
by ELISA. The secretion levels were compared to 0 hour of treatment (set to 
1). Statistical comparisons were conducted using one-way ANOVA, and the 
results are expressed as means ± SE of three independent experiments. **, P < 
0.01; ***, P < 0.001. 
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Figure 3.13: Bleomycin-induced IL-1Ra secretion persists in response to 
prolonged treatment timings and is dose-dependent. Murine fibroblasts 
were treated with 30 µg/ml of bleomycin for the indicated time periods (A) or 
with the indicated concentrations of bleomycin for 20 hours (B). Supernatant 
from the treated cells were then collected and analyzed for IL-1Ra by ELISA. 
The secretion levels were compared to the untreated group (set to 1). 
Statistical comparisons were conducted using one-way ANOVA, and the 
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Chapter 4: Bleomycin-induced IL-1Ra expression is mediated via non-
classical secretory pathway 
Besides being splice variants, sIL-1Ra and icIL-1Ra proteins are also being 
processed differently. While icIL-1Ra isoforms lack signal peptides and 
remain largely intracellular, sIL-1Ra is N-glycosylated and released via the 
classical ER-Golgi secretory pathway (Corradi et al., 1993; Eisenberg et al., 
1990; Hannum et al., 1990). To understand how IL-1Ra is secreted in response 
to bleomycin, we studied the effects of impairing de novo protein synthesis, 
N-glycosylation and secretory processes on bleomycin-induced IL-1Ra 
release. 
 
4.1 Bleomycin-induced IL-1Ra secretion is independent of de novo 
protein synthesis 
Our earlier findings suggested that bleomycin-induced IL-1Ra secretion is 
independent of transcriptional regulation, as the changes in IL-1Ra secretion 
levels in response to bleomycin inversely correlated with that for the mRNA 
steady state levels (Figures 3.11 & 3.12). We therefore determined if 
bleomycin-induced IL-1Ra secretion is dependent on de novo protein 
synthesis by pre-treating primary fibroblasts with cycloheximide for 1 hour, 
followed by treatment with bleomycin for another 20 hours. Cycloheximide is 
produced by Streptomyces griseus and blocks protein synthesis in eukaryotic 
cells by binding to the E-site of the 60S ribosomal subunit (Klinge et al., 2011; 
Pestova and Hellen, 2003; Schneider-Poetsch et al., 2010).  
We detected a significant increase in IL-1Ra secretion in response to 
bleomycin (Figure 4.1), which is consistent with our previous findings. 
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Interestingly, IL-1Ra secretion was also induced when the cells were treated 
with cycloheximide, and the secretion levels were further enhanced when both 
cycloheximide and bleomycin were administered. Our data hence demonstrate 
that the observed increase in IL-1Ra secretion levels due to bleomycin is 
independent of de novo protein synthesis. 
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Figure 4.1: Bleomycin-induced IL-1Ra secretion does not require de novo 
protein synthesis. Murine fibroblasts were pre-treated for 1 hour with vehicle 
or protein synthesis inhibitor, cycloheximide (CHX, 20 µg/ml). The cells were 
subsequently treated with either vehicle or 30 µg/ml of bleomycin for another 
20 hours. Supernatant from the cells were then collected and analyzed for IL-
1Ra by ELISA. The secretion levels were compared to vehicle-treated group 
(set to 1). Statistical comparisons were conducted using Student’s t test and 
the results are expressed as means ± SE of four independent experiments. *, P 
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4.2 Bleomycin-induced IL-1Ra secretion is independent of N-
glycosylation  
Previous studies have shown that sIL-1Ra protein is glycosylated at a N-linked 
glycosylation site (Eisenberg et al., 1991), and mutation of this site affects 
protein secretion efficiency (Han et al., 2005). We hence investigated the 
effect of inhibiting N-glycosylation on bleomycin-induced IL-1Ra secretion 
by pre-treating primary fibroblasts with N-glycosylation inhibitors, 
tunicamycin or 2-deoxy-D-glucose (2DG) for 1 hour, followed by treatment 
with bleomycin for another 20 hours. Tunicamycin inhibits N-
acetylglucosamine transferases, therefore impairing N-linked protein 
glycosylation. 2DG on the other hand, is an analog of glucose, in which its 
second hydroxyl group is replaced by hydrogen and is therefore unable to 
undergo glycolysis.  
We detected a significant increase in IL-1Ra secretion in response to 
bleomycin, and treatment with tunicamycin or 2DG alone significantly 
induced IL-1Ra secretion as well (Figures 4.2a & b). Moreover, pre-treatment 
of primary fibroblasts with tunicamycin or 2DG followed by bleomycin, 
further increased IL-1Ra secretion levels as compared to treatment with 
bleomycin alone. Our data therefore demonstrate that bleomycin-induced IL-
1Ra secretion is independent of N-link protein glycosylation process. 
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Figure 4.2: Inhibition of N-glycosylation does not block bleomycin-
induced IL-1Ra secretion. Murine fibroblasts were pre-treated for 1 hour 
with vehicle or N-glycosylation inhibitors, tunicamycin (TUN, 5 µg/ml) (A) or 
2-Deoxy-D-glucose (2DG, 20 mM) (B). The cells were subsequently treated 
for another 20 hours with either vehicle or 30 µg/ml of bleomycin. 
Supernatant from the cells were then collected and analyzed for IL-1Ra by 
ELISA. The secretion levels were compared to vehicle-treated group (set to 1). 
Statistical comparisons were conducted using Student’s t test and the results 
are expressed as means ± SE of four independent experiments. *, P < 0.05; **, 
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4.3 Secretion of bleomycin-induced IL-1Ra is mediated via non-
classical secretory pathway 
Past studies have demonstrated that the secretion of sIL-1Ra is mediated via 
the classical ER-Golgi secretory pathway (Corradi et al., 1993; Eisenberg et 
al., 1990; Hannum et al., 1990). To investigate if the observed increased in IL-
1Ra levels induced by bleomycin is mediated via the classical secretory 
pathway, vehicle- or bleomycin- treated primary fibroblasts were blocked with 
brefeldin A and monensin 6 hours prior to harvest. Brefeldin A and monensin 
inhibit specific steps within the classical secretory pathway. For instance, 
brefeldin A impairs anterograde transport between ER and the Golgi 
apparatus, while monensin is an ionophore that disrupts the proton gradient 
across the trans-Golgi network.  
We detected a 2.2-fold increase in IL-1Ra secretion in response to 
bleomycin (Figure 4.3), which is consistent with our previous findings. 
However, neither the basal IL-1Ra secretion levels nor the bleomycin-induced 
IL-1Ra secretion levels were impaired when treated with brefeldin A and 
monensin. This suggests that the observed increase in IL-1Ra secretion levels 
due to bleomycin is not mediated via the classical secretory pathway, and is 
likely to be released in an unconventional manner instead. 
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Figure 4.3: Bleomycin induced-IL-1Ra secretion is not blocked by 
brefeldin A and monensin. Murine fibroblasts were treated with vehicle or 
bleomycin for 20 hours. Brefeldin A (B, 1 µg/ml) and monensin (M, 2 µM) 
were added 6 hours prior to collection of supernatant from cells. Supernatant 
from the cells was then analyzed for IL-1Ra using ELISA. The secretion 
levels were compared to vehicle-treated group (set to 1). Statistical 
comparisons were conducted using Student’s t test and the results are 
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Chapter 5: Secretion of IL-1Ra by bleomycin is independent of autocrine 
IL-1 signaling pathway 
Although the effects of IL-1 are antagonized by IL-1Ra, IL-1 is also a potent 
inducer of IL-1Ra expression. Infusion of IL-1α or IL-1β in humans resulted 
in a dramatic increase of IL-1Ra levels within 1 hour (Bargetzi et al., 1993; 
Kopp et al., 1996). While IL-1α and IL-1β protein levels in our system were 
below the detectable limits of the ELISA assays used, it has been 
demonstrated that IL-1α and IL-1ß are able to induce inflammatory processes 
even at low doses (Dinarello, 1998). For instance, IL-1 responses are induced 
when as few as two percent of the IL-1Rs are occupied (Gallis et al., 1989; Ye 
et al., 1992), and previous studies have detected IL-1 signal transduction in 
cells expressing as few as ten IL-1Rs on their cell surfaces (Stylianou et al., 
1992). We thus are interested in understanding the role of IL-1 in bleomycin-
induced IL-1Ra secretion. 
 
5.1 Blocking IL-1α/β does not impair bleomycin-induced IL-1Ra 
secretion 
Previously, we did not observe any significant effects of bleomycin on IL-1α 
mRNA steady state levels, while IL-1β levels was increased by about 3-fold 
when bleomycin was administered (Figure 3.6a & b). Still, the observed 
increase in IL-1Ra secretion could be an indirect consequence of bleomycin 
on IL-1α or IL-1ß protein levels as the IL-1Ra levels were only significantly 
increased after 16 hours of treatment (Figure 3.12). Therefore to study the 
role of IL-1 in bleomycin-induced IL-1Ra secretion, we pre-treated primary 
fibroblasts with neutralizing antibodies against IL-1α or IL-1ß for 1 hour, 
	  	   93 
followed by treatment with bleomycin for another 20 hours. Consistent with 
our earlier observations, IL-1Ra secretion was significantly induced in the 
presence of bleomycin (Figures 5.1 & 5.2). However, neither the basal IL-
1Ra secretion levels nor the bleomycin-induced IL-1Ra secretion levels were 
significantly affected when treated with the neutralizing antibodies against IL-
1α or IL-1ß. This suggests that IL-1α or IL-1ß does not play a role in inducing 
IL-1Ra secretion in response to bleomycin. 
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Figure 5.1: Blocking IL-1α does not impair bleomycin-induced IL-1Ra 
secretion. Murine fibroblasts were pre-treated for 1 hour with vehicle or 
neutralising antibody against IL-1α (2 µg/ml). The cells were subsequently 
treated with either vehicle or 30 µg/ml of bleomycin for another 20 hours. 
Supernatant from the cells were then collected and analyzed for IL-1Ra by 
ELISA. The secretion levels were compared to vehicle-treated group (set to 1). 
Statistical comparisons were conducted using Student’s t test and the results 
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Figure 5.2: Blocking IL-1β does not impair bleomycin-induced IL-1Ra 
secretion. Murine fibroblasts were pre-treated for 1 hour with vehicle or 
neutralising antibody against IL-1β (2 µg/ml). The cells were subsequently 
treated with either vehicle or 30 µg/ml of bleomycin for another 20 hours. 
Supernatant from the cells were then collected and analyzed for IL-1Ra by 
ELISA. The secretion levels were compared to vehicle-treated group (set to 1). 
Statistical comparisons were conducted using Student’s t test and the results 
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5.2 IL-1Ra secretion induced by bleomycin is independent of IL-1R1 
pathway 
To further investigate if the increase in IL-1Ra release by bleomycin is due to 
IL-1 signaling, we treated primary fibroblasts isolated from mice that did or 
did not express IL-1R1 with bleomycin, and analyzed for the secretion levels 
of IL-1Ra. We first validated the genotypes of these two groups of primary 
fibroblasts by assessing for their surface expression of IL-1R1 by flow 
cytometry (Figure 5.3a). As expected, Il1r1+/+ primary fibroblasts expressed 
constitutive levels of IL-1R1 while IL-1R1 was not detected on Il1r1-/- 
primary fibroblasts. Interestingly, the basal levels of IL-1Ra detected for Il1r1-
/- primary fibroblasts were significantly higher as compared to Il1r1+/+ primary 
fibroblasts (Figure 5.3b). While treatment of Il1r1+/+ primary fibroblasts with 
bleomycin significantly upregulated IL-1Ra secretion, abrogation of IL-1R1 
did not prevent the release of IL-1Ra, as shown by the data for the Il1r1-/- 
primary fibroblasts. Moreover, IL-6 secretion levels were not significantly 
changed in the presence of bleomycin, which is a well-studied target gene of 
IL-1 signaling (Figure 5.4). Our results therefore confirmed that bleomycin-
induced IL-1Ra release is independent of IL-1 signal transduction. 
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Figure 5.3: IL-1Ra secretion induced by bleomycin is independent of IL-
1R1 pathway. (A) Murine fibroblasts treated with vehicle or bleomycin (30 
µg/ml) were assessed for surface expression levels of IL-1R1 by flow 
cytometry. IL-1R1 expression by cells treated with vehicle or bleomycin (thin 
and thick lines respectively) were compared to isotype controls (filled 
histograms and dashed lines respectively). Experiment was reproduced three 
times. (B) Supernatant from Il1r1+/+ or Il1r1-/- murine fibroblasts treated with 
vehicle or 30 µg/ml of bleomycin was collected after 20 hours and analyzed 
for IL-1Ra by ELISA. The secretion levels were compared to vehicle-treated 
Il1r1+/+ group (set to 1). Statistical comparisons were conducted using 
Student’s t test and the results are expressed as means ± SE of three 






































































Bleo ! ! + + 
Il1r1+/+ Il1r1-/- 
4 
	  	   98 
 
 
Figure 5.4: Bleomycin does not affect IL-6 secretion. Supernatant from 
murine fibroblasts treated with vehicle or 30 µg/ml of bleomycin was 
collected after 18 - 20 hours and analyzed for IL-6 by ELISA. Statistical 
comparisons were conducted using Student’s t test and the results are 
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Chapter 6: Bleomycin-induced IL-1Ra secretion is dependent on caspase-9 
activation and is independent of DDR 
Genotoxic stress results in DNA lesions that are recognized by sensor 
proteins, which then recruit and activate transducers that initiate the DDR 
process. These transducer proteins, such as ATM and ATR kinases 
subsequently activate effector proteins like p53 via downstream kinases CHK1 
and CHK2. p53 in turn, inhibits cell cycle progression by inducing the 
expression of several target genes such as p21 and 14-3-3σ (Bunz et al., 1998; 
Chan et al., 1999), and activates DNA repair mechanisms. In contrast, 
programmed cell death is activated instead if the DNA damage is too 
extensive to be repaired. This serves to prevent transmission of damaged DNA 
to the daughter cells in order to ensure the survival of the organism.  
Indeed, we have observed previously that DDR was activated when 
primary fibroblasts were treated with bleomycin (Figure 3.1). The cells also 
upregulated ICAM-1, a p53 target gene cell in response to bleomycin 
treatment. Furthermore, bleomycin significantly increased the proportion of 
cells arrested at G2/M phase (Figure 3.2), suggesting that bleomycin induces 
cell cycle arrest due to DDR activation. To study the role of DDR in mediating 
bleomycin-induced IL-1Ra secretion, we first assessed for the effect of 
abrogating p53 on IL-1Ra secretion . 
 
6.1 Bleomycin-induced IL-1Ra secretion is independent of DDR 
signaling  
DDR signaling leads to the activation of effector proteins such as p53, which 
in turn initiates cycle cell arrest to allow for DNA repair before the cell 
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resumes proliferation, or induces apoptosis if the DNA damage is too 
extensive to be repaired. p53 is also known as “guardian of the genome” as it  
is crucial in mediating the effector functions of DDR signaling (Lane, 1992). 
Indeed, p53 is frequently inactivated and mutated in several human cancers 
(Finlay et al., 1989; Levine, 1997; Vogelstein et al., 2000). To determine if the 
increase in IL-1Ra release by bleomycin is mediated by p53, the critical 
effector molecule of DDR, we treated primary fibroblasts isolated from mice 
that did or did not express p53 with bleomycin, and analyzed for IL-1Ra 
secretion levels. We first validated the genotypes of these two groups of 
primary fibroblasts by assessing for their expression p53 by immunoblotting 
(Figure 6.1a). As expected, p53+/+ primary fibroblasts expressed constitutive 
p53 levels but not p53-/- primary fibroblasts. Moreover, treating p53+/+ primary 
fibroblasts with bleomycin increased p53 phosphorylation at serine residue 18, 
while phosphorylated p53 and p21 proteins were both absent in p53-/- cells. 
Using ELISA, significant induction of IL-1Ra secretion was detected when 
p53+/+ primary fibroblasts were treated with bleomycin (Figure 6.1b). 
Abrogation of p53, however, did not prevent the release of IL-1Ra, as shown 
by the data for the p53-/- primary fibroblasts, and IL-1Ra levels secreted by 
bleomycin-treated p53-/- primary fibroblasts were not significantly different 
from p53+/+ primary fibroblasts. Our results therefore indicated that 
bleomycin-induced IL-1Ra release is independent of p53 activity. 
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Figure 6.1: IL-1Ra secretion induced by bleomycin is independent of p53. 
(A) Cell extracts from murine fibroblasts treated with vehicle or bleomycin 
(30 µg/ml) were analyzed for levels of p-p53, total p53 and p21 by 
immunoblotting. GAPDH was included as a loading control. Experiment was 
reproduced three times. (B) Supernatant from p53+/+ and p53-/- fibroblasts 
treated with vehicle or bleomycin were collected after 20 hours and analyzed 
for IL-1Ra by ELISA. The secretion levels were compared to vehicle-treated 
p53+/+ group (set to 1). Statistical comparisons were conducted using Student’s 
t test and the results are expressed as means ± SE of four independent 
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Several studies have shown that transducer proteins ATM and ATR 
kinases are critical for cellular responses to DNA damage induced by 
genotoxic stress (Bartek and Lukas, 2007; Cimprich and Cortez, 2008; Kastan 
and Bartek, 2004; Shiloh, 2003). To understand if ATM and/or ATR kinases 
are responsible for mediating genotoxic stress-induced IL-1Ra secretion, we 
therefore pre-treated primary fibroblasts with an ATM kinase inhibitor, KU-
60019, or with an ATM and ATR kinases inhibitor, caffeine, for 1 hour, 
followed by treatment with bleomycin for another 20 hours. KU-60019 is a 
small molecule inhibitor that specifically targets ATM kinase activity (IC50 
value for ATM is 6.3 nmol / L), and acts on ATR kinase only at higher doses 
(IC50 value for ATR is more than 10 µmol/L) (Golding et al., 2009). Caffeine, 
on the other hand, prevents phosphorylation of ATM and ATR substrates in 
vitro (IC50 values for ATM and ATR are 0.2 mM and 1.1 mM respectively), 
and inhibits checkpoint responses initiated by genotoxic stress (Blasina et al., 
1999; Hall-Jackson et al., 1999; Li et al., 2000; Sarkaria et al., 1999).  
We first studied the effects of KU-60019 and caffeine on ATM and/or 
ATR-mediated DDR signaling by assessing for ICAM-1 expression by flow 
cytometry. As mentioned previously, ICAM-1 is a target gene of p53, which 
in turn, is activated by DDR signaling. Interestingly, the basal expression 
levels of ICAM-1 were decreased further when the cells were treated with 
either KU-60019 or caffeine, suggesting that there were low levels of DDR 
activation in these cells (Figures 6.2a & 6.3a). While bleomycin induced 
ICAM-1 expression, the ICAM-1 induction was reduced when cells were pre-
treated with KU-60019 or caffeine prior to treatment with bleomycin. ICAM-1 
expression was even reduced to near basal levels when cells were pre-treated 
	  	   103 
with caffeine, followed by bleomycin (Figure 6.3a). In addition, inhibitory 
effects of KU-60019 and caffeine on bleomycin-induced ICAM-1 expression 
were dose-dependent (data not shown). 
When assessing the levels of IL-1Ra secretion by ELISA, IL-1Ra 
levels was significantly upregulated in the presence of bleomycin, and this is 
consistent with our previous findings (Figures 6.2b & 6.3b). Treatment with 
KU-60019 or caffeine however, significantly induced IL-1Ra secretion, and 
IL-1Ra levels were further enhanced when cells were pre-treated with KU-
60019 or caffeine prior to treatment with bleomycin. Our combined results 
suggested that DDR, which is activated by genotoxic stress, does not play a 
role in bleomycin-induced IL-1Ra secretion. 
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Figure 6.2: Inhibition of ATM kinase by KU-60019 does not impair 
bleomycin-induced IL-1Ra secretion.  (A) Murine fibroblasts were pre-
treated for 1 hour with vehicle or ATM kinase inhibitor, KU-60019 (10 µM). 
The cells were subsequently treated with either vehicle or bleomycin for 
another 20 hours and were assessed for surface expression levels of ICAM-1 
by flow cytometry. ICAM-1 expression by cells (thick lines) were compared 
to isotype controls (filled histograms). Experiment was reproduced three 
times. (B) Murine fibroblasts were pre-treated for 1 hour with vehicle or KU-
60019 (10 µM). The cells were subsequently treated with either vehicle or 
bleomycin for another 20 hours. Supernatant was collected and analyzed for 
IL-1Ra by ELISA. Statistical comparisons were conducted using Student’s t 
test and the results are expressed as means ± SE of three independent 
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Figure 6.3: Inhibition of ATM and ATR kinases by caffeine does not 
impair bleomycin-induced IL-1Ra secretion. (A) Murine fibroblasts were 
pre-treated for 1 hour with vehicle or ATM and ATR kinases inhibitor, 
caffeine (Caff, 5 mM). The cells were subsequently treated with either vehicle 
or bleomycin for another 20 hours and were assessed for surface expression 
levels of ICAM-1 by flow cytometry. ICAM-1 expression by cells (thick 
lines) were compared to isotype controls (filled histograms). Experiment was 
reproduced three times. (B) Murine fibroblasts were pre-treated for 1 hour 
with vehicle or caffeine (5 mM). The cells were subsequently treated with 
either vehicle or bleomycin for another 20 hours. Supernatant was collected 
after 20 hours and analyzed for IL-1Ra by ELISA. Statistical comparisons 
were conducted using Student’s t test and the results are expressed as means ± 

























































































	  	   106 
6.2 Bleomycin induces the intrinsic apoptosis pathway 
Our earlier findings demonstrated that bleomycin induced cells to undergo 
apoptosis but not necrosis (Figures 3.3 & 3.4). Apoptosis is orchestrated by 
key molecules known as caspases, and is mediated via the extrinsic or intrinsic 
pathway depending on the death stimuli. The extrinsic pathway is initiated 
when the death receptors expressed by the cells bind to extracellular death 
ligands (Nagata, 1999). In contrast, the intrinsic pathway is triggered by 
intracellular signals such as DNA damage and genotoxic drugs, and is 
dependent on the mitochondria (Zamzami and Kroemer, 2001). We henceforth 
studied the role of caspases in our system by monitoring the caspase activities 
with time.  
To do so, we treated primary fibroblasts with bleomycin at various 
time points and used Caspase-Glo assays to assess for changes in caspase-9, 
caspase-8, caspase-3/caspase-7 activities with time. A significant increase in 
caspase-9 activity was detected 8 hours after treatment with bleomycin, and 
the activity levels subsequently returned to basal levels after 24 hours of 
treatment (Figure 6.4). Interestingly, caspase-9 displayed a biphasic activation 
pattern as the activity was significantly increased again after 48 hours of 
treatment with bleomycin. Moreover, increase in caspase-9 activity in 
response to bleomycin correlated with an increase in caspase-3/7 activation, 
suggesting that brief activation of caspase-9 was sufficient to induce 
executioner caspase activities (Figure 6.5a). Activation of caspase-3 was also 
confirmed when primary fibroblasts treated with vehicle or bleomycin were 
assessed for intracellular levels of active caspase-3 by flow cytometry (Figure 
6.5b). Treatment with bleomycin significantly increased the percentage of 
	  	   107 
cells positive for active caspase-3 as much as by 2.5-fold. Caspase-3/7 activity 
increased steadily with time, and was significantly enhanced after 48 hours of 
treatment with bleomycin (Figure 6.5a). Caspase-8 activity displayed a 
similar pattern of activation as shown for caspase-9 activity. However, 
induction of caspase-8 activity was much weaker than that observed for 
caspase-9, and the changes in caspase-8 activation levels in response to 
bleomycin were not significant (Figure 6.6). Our results therefore suggested 
that bleomycin induces the intrinsic apoptosis pathway that is mediated by 
caspase-9, which in turn induces caspase 3/7 and this eventually leads to 
cellular apoptosis (Figure 3.3).  
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Figure 6.4: Bleomycin induces caspase-9 activation. Murine fibroblasts 
were treated with bleomycin (30 µg/ml) for the indicated time periods and 
analyzed for caspase-9 activity by Caspase-Glo 9 assay. The luminescence 
signals are compared to 0 hour of treatment (set to 1). Statistical comparisons 
were conducted using one-way ANOVA, and the results are expressed as 
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Figure 6.5: Bleomycin induces caspase-3/7 activation. (A) Murine 
fibroblasts were treated with bleomycin (30 µg/ml) for the indicated time 
periods and analyzed for caspase-3/7 activity by Caspase-Glo 3/7 assay. The 
luminescence signals are compared to 0 hour of treatment (set to 1).  (B) 
Murine fibroblasts treated with vehicle or bleomycin for 24 hours were 
assessed for caspase-3 activation by staining for active caspase-3 and fixable 
viability stain, followed by flow cytometry analysis. Representative dot-plots 
from three independent experiments are shown. (C) Results in (B) were 
quantified as percentages of cells stained positive for active caspase-3. 
Statistical comparisons were conducted using one-way ANOVA for (A) and 
Student’s t test for (C). The results are expressed as means ± SE of three 
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Figure 6.6: Bleomycin does not induce significant caspase-8 activation. 
Murine fibroblasts were treated with bleomycin (30 µg/ml) for the indicated 
time periods and analyzed for caspase-8 activity by Caspase-Glo 8 assay. The 
luminescence signals are compared to 0 hour of treatment (set to 1). Statistical 
comparisons were conducted using one-way ANOVA, and the results are 
expressed as means ± SE of three independent experiments. ns refers to not 
significant. 
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6.3 Prolonged treatment with bleomycin leads to collapse of the 
mitochondrial membrane potential 
Most of the energy required by a cell is generated by the mitochondria. Energy 
production is dependent on the electron transport chain, which cytochrome c 
makes up an essential component. Apoptosis activates a cascade of signaling 
events that leads to the permeabilization of mitochondrial outer membrane, 
and cytochrome c is subsequently released from the intermembrane space. 
Besides activating caspase-9, continuous release of cytochrome c into the 
cytoplasm also results in the collapse of the electron transport chain, and the 
electrical potential across the mitochondrial inner membrane (ΔΨm) is 
eventually lost. Since mitochondria play a crucial role in initiating intrinsic 
apoptosis pathway and loss of ΔΨm is a critical determinant of cell death 
(Zamzami et al., 1995), we therefore used a fluorescent dye, JC-1 to assess the 
change in ΔΨm by flow cytometry. Cationic JC-1 can be used to analyse the 
mitochondria integrity as the ΔΨm is negative, and acts as a potentiometric 
dye that emits red fluorescence when accumulates in healthy mitochondria. In 
contrast, green fluorescence is detected in cells with depolarized mitochondria 
as the concentration of JC-1 in these cells is low. 
When assessing change in ΔΨm by flow cytometry, we observed that 
the percentages of JC-1 red+ and JC-1 green+ cells remained constant between 
0 to 4 hours of treatment with bleomycin (Figures 6.7a & b). The percentage 
of JC-1 red+ cells however, decreased slightly after 24 hours of treatment, 
whereas a corresponding increase in the percentage of JC-1 green+ cells was 
observed. There was a significant reduction in the percentage of cells stained 
positive for JC-1 red after 48 hours of treatment with bleomycin, whereas the 
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percentage of JC-1 green+ was significantly increased. Our results thus 
indicated that treating cells with bleomycin for a prolonged period of time 
results in a significant loss of ΔΨm. This finding is consistent with our earlier 
observations that bleomycin induces intrinsic apoptosis pathway. 
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Figure 6.7: Prolonged treatment with bleomycin leads to collapse of the 
mitochondrial membrane potential. (A) Murine fibroblasts were treated 
with bleomycin (30 µg/ml) for the indicated time periods and then stained 
with JC-1 for 30 mins, followed by analysis by flow cytometry. JC-1 red+ cells 
represent mitochondrial JC-1 aggregates, whereas JC-1 green+ cells represent 
cytosol monomeric JC-1. Representative dot-plots of JC-1 red/JC-1 green 
bivariate flow cytometry from three independent experiments are shown. (B) 
Results in (A) were quantified as percentages of cells stained positive for JC-1 
red (filled squares) and JC-1 green (open circles). Statistical comparisons were 
conducted using one-way ANOVA and the results are expressed as means ± 
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6.4 Bleomycin-induced IL-1Ra secretion depends on caspases 
We next determined the effect of inhibiting caspases on IL-1Ra secretion by 
pre-treating primary fibroblasts with a general caspase inhibitor (Z-VAD-
FMK) for 1 hour, followed by treatment with bleomycin for another 20 hours. 
Z-VAD-FMK is a cell permeable peptide-based inhibitor that is designed 
according to the common tetrapeptide substrate specificity of the known 
caspases. It can therefore bind to the catalytic site of caspases in an 
irreversible manner and inhibits downstream signaling cascades. Interestingly, 
the percentage of cells expressing active caspase-3 was reduced at basal levels 
when the cells were pre-treated with the general caspase inhibitor, suggesting 
that there were low levels of caspase-3 activation in these cells (Figure 6.8a). 
Bleomycin enhanced caspase-3 activation, and this increase was markedly 
reduced in the presence of the general caspase inhibitor.  
When assessing the effect of inhibiting caspases on IL-1Ra secretion, 
we observed that bleomycin induced primary fibroblasts to secrete higher 
levels of IL-1Ra, and the increase in IL-1Ra secretion levels was significantly 
reduced when the cells were pre-treated with the general caspase inhibitor 
(Figure 6.8b). Furthermore, pre-treatment of primary fibroblasts with caspase-
9 inhibitor (Z-LEHD-FMK) also significantly reduced the increase in IL-1Ra 
secretion by bleomycin (Figure 6.9). Similarly, pre-treatment of the cells with 
caspase-3 inhibitor (Z-DEVD-FMK) reduced the increase in IL-1Ra secretion 
in response to bleomycin (Figure 6.10), but the reduction was less than that 
observed for caspase-9 inhibitor. Collectively, our results demonstrated that 
genotoxic stress induced by bleomycin activates the intrinsic apoptosis 
pathway, and bleomycin-induced IL-1Ra secretion is dependent on caspase-9 
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and to a lesser extent, on caspase-3. 
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Figure 6.8: Significant inhibition of bleomycin-induced IL-1Ra secretion 
by the general caspase inhibitor (Z-VAD-FMK). Murine fibroblasts were 
pre-treated for 1 hour with vehicle or Z-VAD-FMK (20 µM), followed by 
treatment with either vehicle or 30 µg/ml of bleomycin for the next 20 hours. 
(A) The cells were then assessed for caspase-3 activation by staining for active 
caspase-3 and fixable viability stain, followed by flow cytometry analysis. 
Representative dot-plots from two independent experiments are shown. (B) 
Supernatant from treated cells was collected and analyzed for IL-1Ra by 
ELISA. Statistical comparisons were conducted using Student’s t test and the 
results are expressed as means ± SD of one of four independent experiments 
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Figure 6.9: Significant inhibition of bleomycin-induced IL-1Ra secretion 
by the caspase-9 inhibitor (Z-LEHD-FMK). Murine fibroblasts were pre-
treated for 1 hour with vehicle or Z-LEHD-FMK (10 µM), and were 
subsequently treated with either vehicle or 30 µg/ml of bleomycin for another 
14 hours. Supernatant was collected and analyzed for IL-1Ra by ELISA. 
Statistical comparisons were conducted using Student’s t test and the results 
are expressed as means ± SD of one of three independent experiments done in 
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Figure 6.10: Bleomycin-induced IL-1Ra secretion partially depends on 
caspase-3. Murine fibroblasts were pre-treated for 1 hour with vehicle or Z-
DEVD-FMK (10 µM), and were subsequently treated with either vehicle or 30 
µg/ml of bleomycin for another 14 hours. Supernatant was collected and 
analyzed for IL-1Ra by ELISA. Statistical comparisons were conducted using 
Student’s t test and the results are expressed as means ± SD of one of three 
independent experiments done in triplicates. **, P < 0.01; ***, P < 0.001.  
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Chapter 7: IL-1Ra released in response to bleomycin dampens inflammatory 
responses by inhibiting IL-1 signaling 
IL-1Ra is an endogenous inhibitor of IL-1 and it acts by competing with IL-1 
for binding onto IL-1R1. IL-1Ra therefore plays a critical role in regulating 
IL-1–induced inflammation, as IL-1 is a potent activator of inflammatory 
responses. Binding of IL-1 to IL-1R1 activates a series of signaling events 
leading to the activation of NF-κB, which regulates the transcription of several 
inflammatory genes such as TNF and interleukin-6 (IL-6) (O'Neill et al., 
1990). Activation of NF-κB transcription activity is important in maintaining 
and amplifying the initial inflammatory response induced by IL-1. 
Interestingly, IL-1 expression is also regulated by NF-κB, thus activation of 
NF-κB by IL-1 establishes a positive feedback loop. Since IL-1 responses can 
be induced even when only as few as two percent of the IL-1Rs are occupied 
(Gallis et al., 1989; Ye et al., 1992), much focus has been given to targeting 
IL-1 activity in several inflammatory diseases (Dower et al., 1986; Gallis et 
al., 1989). The inhibitory property of IL-1Ra in IL-1 signaling has been 
studied extensively in several autoimmunity disorders (Badovinac et al., 1998; 
Bresnihan et al., 1998) and is currently used for treatment of rheumatoid 
arthritis (Fleischmann et al., 2006). 
 
7.1 IL-1Ra secreted by bleomycin-treated cells is bioactive 
We designed and performed an assay to determine if bleomycin-induced IL-
1Ra could affect IL-1 signaling. We treated the first set of fibroblasts with 
bleomycin for 24 hours, before transferring the supernatant from these cells to 
a second set of fibroblasts prepared from the day before. The second set of 
	  	   120 
fibroblasts were subsequently incubated with the newly transferred 
supernatant for 1 hour, and were treated with increasing doses of recombinant 
IL-1α for another 6 hours. The treated cells were then harvested and analyzed 
for IL-6 mRNA expression levels by real time PCR.  
We observed that IL-6 gene expression was upregulated further with 
increasing doses of recombinant IL-1α (Figure 7.1a). Cells that received 
supernatant from the bleomycin treatment group also expressed higher levels 
of IL-6 when increasing concentrations of IL-1α were administered. However, 
the increase in IL-6 mRNA levels was more gradual for the bleomcyin 
treatment group than the control group (1.9-fold increase versus 3-fold 
increase respectively). The observed change in IL-6 mRNA levels was 
dependent on IL-1 signaling as abrogation of IL-1R1 drastically reduced IL-6 
expression even when the highest concentration of IL-1α was used (Figure 
7.1b). Our results therefore indicate that bleomycin-induced IL-1Ra is 
bioactive and can impair IL-1 signaling. 
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Figure 7.1: IL-1Ra secreted by bleomycin-treated cells is bioactive. (A) 
Supernatant from murine fibroblasts treated with vehicle or 30 µg/ml of 
bleomycin was collected after 24 hours and transferred to a new set of murine 
fibroblasts. After incubation with the supernatant for 1 hour, the cells were 
treated with vehicle or recombinant IL-1α at the indicated concentrations for 6 
hours. The cells were then assessed for IL-6 mRNA expression by quantitative 
real-time RT-PCR. The data for all samples were normalised to their 
respective HPRT mRNA levels, and compared to vehicle-treated (set to 1). (B) 
Supernatant from murine fibroblasts was collected after 24 hours and 
transferred to Il1r1+/+ or Il1r1-/- fibroblasts. After incubation with the 
supernatant for 1 hour, the murine fibroblasts were treated with recombinant 
IL-1α (100 fg/ml) for 6 hours. The cells were then assessed for IL-6 mRNA 
expression by quantitative real-time RT-PCR. The data for the samples were 
normalised to their respective HPRT mRNA levels, and compared to Il1r1+/+ 
group (set to 1). Statistical comparisons were conducted using one-way 
ANOVA for (A) and Student’s t test for (B). The results are expressed as 
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Chapter 8: Role of IL-1 signaling in a mouse model of spontaneous B cell 
lymphoma 
Our findings demonstrated that different types of genotoxic stress are capable 
of inducing cells to secrete IL-1Ra. This suggests that the immediate cellular 
response to acute genotoxic stress is to initiate apoptosis and to secrete anti-
inflammatory factors that can dampen inflammatory responses in the 
microenvironment. Persistent DNA damage signaling on the other hand, 
induced cells to enter cellular senescence after 6 to 10 days, and these 
senescent cells in turn released several inflammatory mediators that drove 
inflammatory responses and promoted cancer cell invasiveness (Rodier et al., 
2009). The same group also showed that that the senescence-associated 
cytokine network was regulated by cell surface-bound IL-1α (Orjalo et al., 
2009).  
In other studies however, cellular senescence was induced when liver 
tissues were treated with a fibrosis-inducing agent or when p53 was restored 
in tumors (Krizhanovsky et al., 2008; Lujambio et al., 2013; Xue et al., 2007). 
The senescent cells were shown to release several factors, including IL-1 that 
activated immune cells, leading to immune cell-mediated clearance of tumor. 
These data suggest that genotoxic stress and DDR activation are intricately 
linked to IL-1 signaling, which in turn may promote or prevent cancer 
progression. To study the physiological relevance of IL-1 signaling in 
tumorigenesis, we therefore crossed Il1r1-/- mice with a spontaneous B cell 
lymphoma mouse model and monitored for the effect of IL-1R1 ablation on 
tumor progression in these mice. 
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We previously characterized the Eµ-myc mouse model by 
demonstrating that tumorigenic early proliferating B cells, which were present 
in the peripheral blood of the mutant mice, were spontaneously reduced when 
the mice were between 41 – 65 days of age (Croxford et al., 2013). 
Subsequent DNAM-1 blocking experiments, NK, CD8+ and/or CD4+ T cell 
depletion assays showed that DDR-induced ligand signaling to the immune 
cells was important in enhancing immune recognition of the tumor cells. 
Reappearance of the tumor cells in some mice at the later stage of 
tumorigenesis suggests that these tumor cells had acquired additional 
mutations that enabled them to escape immune surveillance.  
 
8.1 Spontaneous regression of early Eµ-myc-induced murine B cell 
leukaemia  
Eµ-myc mice are genetically modified to overexpress the murine c-Myc 
oncogene that is coupled to Ig heavy chain enhancer (Eµ). These mice 
subsequently develop spontaneous immature B cell lymphomas analogous to 
human Burkitt lymphoma (Adams et al., 1983). We have previously 
characterized the time course for blood tumor development in the Eµ-myc 
mice and immature B cell tumor was detected in the blood of Eµ-myc mice as 
early as 21 days of age (Figure 8.1a). The tumor cells were identified based 
on their expression of IgM and B220, and were present in two main 
phenotypes - IgM- B220low and IgM+ B220low.  
Our data from a large number of mice revealed that the percentage of 
B220low tumor cells regressed sharply when the mutant mice were between 
day 41 to 65 days of age, suggesting a synchronized mechanism of control 
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(Figure 8.1b). Sporadic recurrence of cancer was observed in some mice 
beyond 65 days old as a spontaneous increase in the percentage of B220low 
tumor cells in the blood was detected in these mice. 80% of these mice had 
tumors that were predominately IgM- B220low while the remaining 20% had 
tumors that were predominately IgM+ B220low (Croxford et al., 2013). 
Since previous studies have shown that overexpression of the c-MYC 
oncogene induces DNA damage in cells (Pusapati et al., 2006; Ray et al., 
2006), we ascertained this by examining the expression of several DDR 
markers by immunoblotting. As discussed in the earlier sections, genotoxic 
stress activates transducers such as ATM and ATR kinases that initiate the 
DDR process and activate downstream kinases CHK1 and CHK2. Effector 
proteins like p53 are then phosphorylated and activated by downstream 
kinases, and inhibits the cell cycle progression by inducing expression of 
several target genes such as p21 and 14-3-3σ (Bunz et al., 1998; Chan et al., 
1999), thus allowing for DNA repair mechanisms to be carried out. In 
contrast, programmed cell death is activated if the DNA damage is too 
extensive to be repaired. Our western blot analysis showed that tumor cells 
derived from the Eµ-myc mice upregulated the expression levels of γH2AX, p-
ATM and p-p53 (Figure 8.1c), suggesting that the DDR signaling is activated 
in the tumor cells that overexpress the c-MYC oncogene . 
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Adapted from Blood 121, 2512 – 21 (2013)     
 
Figure 8.1: Blood tumor load in Eμ-myc+/- mice regresses spontaneously. 
(A) Cells derived from the peripheral blood were stained for anti-B220 and 
anti-IgM antibodies, and were subsequently assessed by flow cytometry. 
B220low populations in Eµ-myc mice were identified by the oval gates. (B) 
Blood tumor load at the indicated time points was determined by flow 
cytometry and the results are represented as the percentage of B220low cells in 
the blood for each mouse examined. The mean tumor load at each time-point 
was represented as a diamond with 95% confidence limit. (C) B220low cells 
were harvested and purified from WT or Eµ-myc mice, and were assessed for 
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8.2 IL-1R1 deficiency does not significantly affect survival of Eµ-myc+/- 
mice 
We monitored the survival of Il1r1-/-, Eµ-myc+/- mice over a period of 300 
days, and compared to that of Il1r1+/+, Eµ-myc+/-. Mice of both genotypes have 
similar survival proportions between day 21 to 100 (Figure 8.2). Between day 
110 to 250 however, the survival proportions between the two genotypes are 
different as we observed that 50% of the Il1r1-/-, Eµ-myc+/- mice survived till 
the end of 150 days as compared to the Il1r1+/+, Eµ-myc+/- mice (35%). Both 
group of mice had a survival proportion of 22% between day 260 to 300. As 
the medial survival time for Il1r1+/+, Eµ-myc+/- mice was not significantly 
different from that of the Il1r1-/-, Eµ-myc+/- mice (113.5 days and 138 days 
respectively), our data suggested that ablation of IL-1R1 did not significantly 
affect the survival of the Eµ-myc+/- mice. 
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Figure 8.2: Loss of IL-1R1 does not significantly affect the survival of Eμ
-myc+/- mice. Survival of Il1r1+/+, Eµ-myc+/- and Il1r1-/-, Eµ-myc+/- mice were 
tracked over a period of 300 days and analysed using the Kaplan-Meier 
method. Statistical comparisons were conducted using Log-rank (Mantel-Cox) 
and Gehan-Breslow-Wilcoxon tests. Median survival times for Il1r1+/+, Eµ-
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8.3 Il1r1-/-, Eµ-myc+/- mice have higher initial tumor burden than 
Il1r1+/+, Eµ-myc+/- mice 
We subsequently monitored the blood tumor load of Il1r1-/-, Eµ-myc+/- mice 
over a period of 130 days, and compared with that for Il1r1+/+, Eµ-myc+/-. We 
defined relapse as an increase in tumor load greater than 20% after the 
regression period as mice consistently display tumor loads of 20% or less 
during the regression period. Prior to 40 days of age, Il1r1-/-, Eµ-myc+/- mice 
had 60 to 70 % of blood tumor load at as compared to 40 to 60 % of B220low 
cells for Il1r1+/+, Eµ-myc+/- mice (Figure 8.3). During the regression phrase 
(41 – 65 days of age), a sharp decrease in the percentage of B220low cells was 
observed for the Il1r1+/+, Eµ-myc+/- mice, which is consistent with our previous 
findings (Croxford et al., 2013). The same was observed for the Il1r1-/-, Eµ-
myc+/- mice; however, regression of the B220low cells was delayed in these 
mice as shown by the consistently higher percentage of B220low cells up to 70 
days of age. The higher percentage of B220low cells detected could be due to 
the significantly higher percentage of IgM- B220low cells detected in the blood 
of Il1r1-/-, Eµ-myc+/- mice between 41 to 70 days of age as compared to that 
for the Il1r1+/+, Eµ-myc+/- mice (Figure 8.4). In contrast, no significant 
difference in the percentage of IgM+ B220low cells between Il1r1+/+, Eµ-myc+/- 
mice and Il1r1-/-, Eµ-myc+/- mice was detected. This suggests that IL-1 
signaling plays a role in mediating the spontaneous loss of IgM- B220low cells 
during the regression period. 
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Figure 8.3: Longitudinal analysis of tumor load in peripheral blood of 
Il1r1+/+, Eμ-myc+/- or Il1r1-/-, Eμ-myc+/- mice. Blood tumor load at the 
indicated time points was assessed by flow cytometry and the results are 
represented as the percentage of B220low cells in the blood for each mouse 
examined. The mean tumor load at each time-point was represented as a 
diamond with 95% confidence limit. The black line across the plot refers to 
the mean percentage of B220low cells in the blood of WT mice. The various 
shaded segments in the graph indicate the progression of tumorigenesis: pre-
regression (21 – 40 days, white segment), regression (41 – 65 days, gray 
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Figure 8.4: Analysis of B220low cell sub-types in the blood of Il1r1+/+, Eμ-
myc +/- and Il1r1-/-, Eμ-myc +/- mice. Blood tumor load at the indicated time 
intervals was assessed by flow cytometry. Top and bottom graphs represent 
the respective percentages of IgM+ B220low and IgM- B220low cells sub-types 
in the blood of mice (n ≥ 4 per time interval). Il1r1+/+, Eµ-myc+/- and Il1r1-/-, 
Eµ-myc+/- mice are represented as blue and red bars respectively. Statistical 
comparisons were conducted using Student’s t test and the results are 
expressed as means ± SD. ***, P < 0.001.  
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8.4 Peripheral blood lymphocytes do not express high levels of IL-1R1 
on their cell surfaces 
We have previously shown that DDR-induced ligand signaling to immune 
cells such as NK, CD8+ and CD4+ T cells played an important role in 
enhancing immune recognition, which eventually led to the spontaneous 
rejection of tumor cells in vivo (Croxford et al., 2013). To understand if IL-1 
signaling pathway plays a role in mediating the loss of IgM- B220low cells 
during the regression period, we assessed for the cell surface expression of IL-
1R1 on B220+ cells, as well as on NK1.1+, CD8+ and CD4+ T cells (Figure 
8.5). As expected, IL-1R1 was not expressed by the lymphocytes in Il1r1-/-, 
Eµ-myc+/- mice; however, we also did not detect IL-1R1 expression on the 
NK1.1+, CD8+ and CD4+ T cells that were derived from the Il1r1+/+, Eµ-myc+/-. 
This suggests that the impaired loss of IgM- B220low cells observed for Il1r1-/-, 
Eµ-myc+/- mice during the regression phrase could be mediated by other high 
IL-1R1-expressing cells such as fibroblasts or endothelial cells present in the 
microenvironment. 
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Figure 8.5: Peripheral blood lymphocytes do not express IL-1R1. (A & B) 
Subsets of lymphocytes were identified by staining the peripheral blood cells 
with anti-B220, anti-NK1.1, anti-CD8 and anti-CD4 antibodies by flow 
cytometry. (C - F) The various subsets of lymphocytes were subsequently 
assessed for the surface expression levels of IL-1R1 by flow cytometry. IL-
1R1 expression by cells from Il1r1+/+, Eµ-myc+/- and Il1r11-/-, Eµ-myc+/- mice 
(blue and red lines respectively) were compared to isotype controls (filled 
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Chapter 9: TLR1/2 agonist increases anti-cancer effect of chemotherapy 
While our study so far has been focused on the effect of genotoxic stress on 
the regulation of IL-1 family, as well as the effect of ablating IL-1R1 signaling 
in tumorigenesis, we are also interested in studying the reverse – whether 
inflammatory mediators can enhance the immunomodulatory effects of 
genotoxic stress caused by chemotherapy. To test the above hypothesis, we 
pre-treated tumor cells with a TLR1/2 agonist, Pam3CSK4 prior to treatment 
with a chemotherapy drug, Arabinofuranosyl Cytidine (Ara-C) and assessed 
for the immunomodulatory effects of this combination therapy on tumor cells 
in vitro and in vivo.  
 
9.1 Pam3CSK4 enhances immunomodulatory and anti-tumor effects of 
Ara-C both in vitro and in vivo 
Treatment of B cell leukemia cell line, EµM2 cells with either Ara-C or 
Pam3CSK4, led to upregulation of several co-stimulatory molecules on the cell 
surface, such as CD80, CD86, ICAM-1 and H-2Kb (Figure 9.1a). Expression 
of CD69 however, was increased only in the presence of Pam3CSK4 but not 
Ara-C. When EµM2 cells were pre-treated with Pam3CSK4 followed by Ara-
C, this enhanced the expression of CD80, CD86, ICAM-1 and H-2Kb as 
compared to Ara-C or Pam3CSK4 single treatment. Our data suggested that 
Pam3CSK4 enhances the effect of Ara-C on the expression of co-stimulatory 
molecules on tumor cells. 
We next compared the efficacy of this combination treatment regime 
with the single Ara-C or Pam3CSK4 treatment by assessing the tumorigenic 
effects of the treated tumor cells in vivo. Tumor cells that were treated with 
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Pam3CSK4 and/or Ara-C, were adoptively transferred to the C57BL/6 mice. 
Prior to this, the EµM2 cells were first transduced with a retroviral plasmid 
expressing the congenic marker Thy1.1 so as to enable detection of these 
adoptively transferred tumor cells in vivo. Mice that received DMSO- or 
Pam3CSK4-treated EµM2 cells all died by 13 to 14 days post injection (Figure 
9.1b). On the other hand, mice that were injected with Ara-C-treated tumor 
cells survived longer than mice that were injected with DMSO- or Pam3CSK4-
treated EµM2 cells. Interestingly, the survival rate was significantly enhanced 
in the group of mice that received Pam3CSK4- and Ara-C-treated EµM2 cells.  
We then assessed for the levels of tumor load in the spleen and blood 
of these mice by flow cytometry. In agreement with our analyses of mice 
survival after adoptive transfer, the tumor levels detected in the spleens of 
mice that received Pam3CSK4- and Ara-C-treated EµM2 cells were 
significantly lower than that observed for mice that received Pam3CSK4- or 
Ara-C-treated EµM2 cells (Figure 9.1c). Similarly, we observed a lower 
percentage of tumor levels in the blood of mice that received Ara-C-treated 
EµM2 cells as compared to that for mice that received DMSO- or Pam3CSK4-
treated EµM2 cells, and the levels were further reduced in mice that received 
Pam3CSK4- and Ara-C-treated EµM2 cells (Figure 9.1d). This demonstrates 
that Pam3CSK4 enhances the effect of Ara-C on the expression of 
immunomodulatory ligands on tumor cells in vitro, which in turn contributes 
to the anti-tumor effects of the combination treatment in vivo. 
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Figure 9.1: Pam3CSK4 enhances immunomodulatory and anti-tumor 
effects of Ara-C in vitro and in vivo. (A) EµM2 cells subjected to indicated 
treatments were assessed for surface expression levels of CD69, CD80, CD86, 
ICAM-1 and H-2Kb by flow cytometry (black line), and were compared to 
their respective isotype control stainings (filled histograms). (B) Kaplan-Meier 
survival curve of C57BL/6 mice injected with 5 x 105 of Pam3CSK4 and/or 
Ara-C-treated EµM2 cells. Statistical comparisons were conducted using the 
log-rank test. P < 0.05; Ara-C vs Ara-C + Pam3CSK4. (C & D) 5 x 105 of 
DMSO, Ara-C, Pam3CSK4 or Pam3CSK4 + Ara-C-treated Thy1.1-expressing 
EµM2 cells were injected intravenously into the recipient C57BL/6 mice. The 
mice were then analyzed for tumor burden in the spleen (C) and blood (D) by 
flow cytometry on day 5, 6, 8 and 11 post injection. Statistical comparisons 
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9.2 Pam3CSK4 modulates Ara-C induced NF-κB activation 
To investigate the possible molecular mechanisms that contributed to the 
protective effect of Pam3CSK4 and Ara-C co-treatment, we first analyzed for 
the expression of several key molecules of the DDR signaling pathway. Our 
western blot analysis showed that phosphorylation levels of H2AX and p53 
were elevated in response to Ara-C treatment as compared to that observed for 
EµM2 cells treated with DMSO or Pam3CSK4 (Figure 9.2a). The increase in 
protein levels for γH2AX and p-p53 was also observed for EµM2 cells treated 
with Pam3CSK4 and Ara-C. Interestingly, treatment with Pam3CSK4 alone 
increased the expression of p21, a p53 target gene, although phosphorylation 
of p53 was not observed in this treatment group.  
Activation of NF-κB occurs via the MYD88 pathway when Pam3CSK4 
binds to its receptors. In addition, NF-κB can also be activated by genotoxic 
stress that induces DDR. Activation of DNA damage-responsive kinase ATM 
leads to its association with NEMO, and subsequently promotes the activation 
of NF-κB signaling pathway (Wu et al., 2006; Yamamoto et al., 2003). To 
determine the effect of Pam3CSK4 on Ara-C-induced NF-κB signaling, we 
studied the expression of several molecules of the NF-κB pathway. IκBα, an 
inhibitor of NF-κB, was significantly degraded after 16 hours of treatment 
with Ara-C alone. In contrast, the phosphorylation levels of transcription 
factor p65, a subunit of NF-κB, increased after 1 hour of treatment with Ara-C 
and the phosphorylation levels returned to basal levels after 3 hours of Ara-C 
treatment. Our results showed that that EµM2 cells treated with both 
Pam3CSK4 and Ara-C displayed significantly higher levels of IKKα/β 
phosphorylation and prolonged phosphorylation of p65 as compared to Ara-C 
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treatment alone (Figure 9.2b). Besides, combination treatment induced faster 
and higher levels of IκBα degradation as compared to Ara-C treatment. This 
suggests that Pam3CSK4 enhances and prolongs Ara-C-induced NF-κB 
activation, but has no effect on Ara-C-induced p53-mediated DDR pathway. 
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Figure 9.2: Pam3CSK4 modulates Ara-C induced NF-κB activation. (A) 
Immunoblot analysis of 1 µM Ara-C or DMSO-treated EµM2 cells pretreated 
with 1 µg/ml Pam3CSK4 and probed with antibodies for the indicated DNA 
damage response markers (left panel). Protein levels were quantitated and 
normalized to their respective GAPDH expression levels and DMSO-treated 
EµM2 cells (right panel). (B) 1 µM Ara-C induced degradation of the NF-κB 
inhibitor IκBα and phosphorylation of IKKα, IKKβ and p65 in 1 µg/ml 
Pam3CSK4 or mock treated EµM2 cells at the indicated times. 
Phosphorylation was detected by Western blotting with the use of phospho-
IKKα/β-, IKKα-, IKKβ-, IκBα-, phospho-p65- and p65-specific antibodies. 
The experiments were reproduced at least twice. 
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9.3 Enhanced immunomodulatory effects of combination treatment is 
independent of p53 
To investigate if p53 plays a role in enhancing the immunomodulatory effects 
of the combination treatment on tumor cells in vitro, we transduced EµM2 
cells with control vector or p53 shRNA, and assessed for the effect of p53 
inhibition on the expression of immunomodulatory ligands on the tumor cells. 
Consistent with our earlier observations, treating EµM2 cells with either Ara-
C or Pam3CSK4 resulted in an upregulation of CD80, CD86, ICAM-1 and H-
2Kb levels as compared to that for DMSO-treated group (Figure 9.3a). 
Expression of CD69 however, was upregulated only in the presence of 
Pam3CSK4 but not Ara-C. The expression levels for these co-stimulatory 
molecules were further enhanced in the combination treatment group as 
compared to the single treatment groups with either Ara-C or Pam3CSK4. This 
is consistent with our earlier findings (Figure 9.1a). Interestingly, genetic 
inhibition of p53 by as much as 3.3-fold (Figures 9.3b & c) did not affect 
Pam3CSK4- and/or Ara-C-induced expression of these co-stimulatory 
molecules (Figure 9.3a), suggesting that the enhanced immunomodulatory 
effects of Pam3CSK4 and Ara-C on EµM2 cells are independent of the p53 
signaling pathway.  
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Figure 9.3: Additive effects of Pam3CSK4 on Ara-C-induced 
immunomodulatory molecules are not mediated by p53. (A) EµM2 cells 
transduced with control plasmid (thin line) or p53-specific shRNA (thick line) 
were treated as indicated. Cell surface expression levels of CD69, CD80, 
CD86, ICAM-1 and H-2Kb were assessed by flow cytometry. The specific 
antibody stainings for control plasmids and p53-specific shRNA transduced 
EµM2 cells were compared to the isotype controls (filled histograms and 
dashed lines respectively). (B) Transduced EµM2 cells were probed for total 
p53 by immunoblotting. GAPDH was included as a loading control. 
Experiment was reproduced three times. (C) Protein levels in (B) were 
quantified and normalized to their respective GAPDH expression levels and to 
the control group. Statistical comparisons were conducted using Student’s t 
test and the results are expressed as means ± SE of three independent 
experiments. *, P < 0.05.  
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9.4 Enhanced immunomodulatory effects of combination treatment is 
dependent on NF-κB 
Since our results suggested that Pam3CSK4 enhances and prolongs Ara-C-
induced NF-κB activation (Figure 9.2), we next determined if NF-κB is 
important for enhancing the immunomodulatory effects of the combination 
treatment on tumor cells in vitro. We first transduced EµM2 cells with a 
control vector or a vector encoding for non-functional, mutant IκB-α (IκBα-
SR) and assessed for the effect of p53 inhibition on the expression of 
immunomodulatory ligands on the tumor cells. Consistent with our earlier 
observations, treatment of EµM2 cells with either Ara-C or Pam3CSK4 
upregulated several co-stimulatory molecules on the tumor cells as compared 
to the DMSO-treated group (Figure 9.4a). The expression levels for these co-
stimulatory molecules were further enhanced in the combination treatment 
group as compared to the single treatment groups with either Ara-C or 
Pam3CSK4. Interestingly, overexpressing IκBα-SR in EµM2 cells by as much 
as 2-fold (Figures 9.4b & c) impaired the responsiveness of the tumor cells to 
Ara-C or Pam3CSK4 and even abrogated the constitutive expression of CD86. 
Furthermore, observed additive effects of the combination treatment on the co-
stimulatory molecules were inhibited in cells that overexpressed IκBα-SR 
(Figure 9.4a). In summary, our results suggested that Pam3CSK4 enhanced the 
immunomodulatory effects of Ara-C-treated EµM2 cells via the NF-κB 
pathway, therefore increasing the anti-cancer effects of Ara-C treatment in 
vivo. 
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Figure 9.4: Additive effects of Pam3CSK4 on Ara-C-induced 
immunomodulatory molecules are mediated by NF-κB pathway. (A) 
EµM2 cells transduced with control plasmid (thin line) or IκBα super 
repressor (IκBα-SR) mutant (thick line) were treated as indicated. Cell surface 
expression levels of CD69, CD80, CD86, ICAM-1 and H-2Kb were assessed 
by flow cytometry. The specific antibody stainings for control plasmids and 
IκBα-SR transduced EµM2 cells were compared to isotype controls (filled 
histograms and dashed lines respectively). (B) Transduced EµM2 cells were 
probed for IκBα by immunoblotting. GAPDH was included as a loading 
control. Experiment was reproduced three times. (C) Protein levels in (B) 
were quantified and normalized to their respective GAPDH expression levels 
and to the control group. Statistical comparisons were conducted using 
Student’s t test and the results are expressed as means ± SE of three 
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Chapter 10: Discussion and future perspectives 
10.1 Summary of key findings 
We have shown that IL-1Ra secretion is upregulated by different kinds of 
genotoxic stress stimuli, such as chemotherapy and telomere dysfunction. In 
contrast, bleomycin had no observable effects on IL-1R1 cell surface 
expression levels, and IL-1α and IL-1β proteins were not detected. 
Interestingly, IL-1Ra mRNA steady state levels were rapidly downregulated in 
response to chemotherapy, but IL-1Ra secretion continued to increase even 
after 48 hours of treatment with bleomycin. Besides transcriptional regulation, 
chemotherapy-induced IL-1Ra secretion also occurs independently of de novo 
protein synthesis and N-glycosylation. IL-1Ra release was not impaired by 
brefeldin A and monensin, suggesting that the secretion of IL-1Ra is mediated 
via the non-conventional secretory pathway. Blockade of IL-1 signaling by IL-
1α or IL-1β neutralizing antibodies, or by ablating IL-1R1 did not affect 
chemotherapy-induced IL-1Ra secretion, thus indicating that IL-1 signaling 
does not play a role in this system. In addition, IL-1Ra release by bleomycin 
occurs independently of DDR as inhibition of ATM and/or ATR or abrogation 
of p53 did not impair the increase in IL-1Ra secretion induced by bleomycin. 
We subsequently demonstrated that bleomycin activates caspases mediating 
the intrinsic apoptosis pathway, and chemotherapy-induced IL-1Ra secretion 
is significantly impaired by a general caspase inhibitor as well as by a caspase-
9 inhibitor. IL-1Ra secretion in response to bleomycin is only partially 
impaired when caspase-3 is inhibited. We also showed that IL-1Ra secreted by 
bleomycin-treated cells is bioactive, and can impair IL-1-induced IL-6 gene 
expression. Overall, our data suggests that genotoxic stress induces IL-1Ra 
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secretion, which in turn impairs IL-1 signaling and IL-1Ra secretion due to 
bleomycin is dependent on caspases that mediate the intrinsic apoptosis 
pathway (Figure 10.1). Our findings also indicate that IL-1R1 deficiency does 
not significantly affect survival of Eµ-myc+/- mice, but plays a role in 
mediating the spontaneous loss of IgM- B220low cells during the regression 
period. Lastly, we established that the adjuvanticity effect of Pam3CSK4 on 
Ara-C-treated tumor cells is mediated via NF-κB signaling. 
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Figure 10.1: Genotoxic stress induces caspase-dependent IL-1Ra secretion 
to prevent or dampen inflammatory responses. Genotoxic stress induces 
IL-1Ra secretion via caspase-9 and caspase-3, which are involved in the 
intrinsic apoptosis pathway and IL-1Ra is secreted via the non-conventional 
secretory pathway. When released by the damaged cell, IL-1Ra binds to IL-
1R1 in an autocrine or paracrine manner, thereby competing with IL-1 for 
binding and impairing IL-1-mediated signaling on these cells.  
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10.2 Genotoxic stress-induced IL-1Ra secretion is regulated by caspases 
Our study demonstrates that bleomycin is a potent inducer of IL-1Ra 
secretion. Bleomycin is a chemotherapy drug used in clinics for treatment of 
several types of human cancer (Bayer et al., 1992; Einhorn, 2002). By 
generating reactive oxygen species, it induces DNA lesions that in turn trigger 
the DDR pathway (Giloni et al., 1981; Mahmutoglu et al., 1987). Although 
key DDR markers including γH2AX, phosphorylated p53 protein levels and 
p21 mRNA levels were upregulated in response to bleomycin, there was no 
significant difference in p21 protein levels between the untreated and the 
treated fibroblasts. In contrast, ICAM-1 expression was significantly 
upregulated on the treated cells as compared to the untreated group, 
suggesting that bleomycin had activated the effector functions of p53. The 
regulation of p21 protein expression in this case may have occurred 
independently of p53 activity, as suggested by the high levels of p21 detected 
in the untreated cells. While previous findings showed that p53 induces p21 
gene expression following DNA damage (Di Leonardo et al., 1994; el-Deiry et 
al., 1994; Xiong et al., 1993), other studies have also suggested that p21 
induction can occur independently of p53. For instance, a recent study 
demonstrated that p21 expression was increased in p53-deficient cells, and the 
increase in p21 expression is dependent on CHK2 (Aliouat-Denis et al., 2005). 
Therefore, basal activity of CHK2 may account for the high protein levels of 
p21 expressed by the untreated cells in our study. Indeed, we observed that 
treating primary murine fibroblasts with either the ATM kinase inhibitor 
(KU60019) or with caffeine led to the downregulation of ICAM-1 , suggesting 
that there is some basal Chk2 activity probably due to the conditions of cell 
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culture. 
Treatment with bleomycin induced the cells to undergo apoptosis, 
however this process was delayed as the percentage of apoptotic cells was 
only significantly increased after 24 hours of treatment. This may be due to 
the hydrophilic nature of bleomycin that resulted in its inefficient uptake by 
cultured cells. As shown in a study, radiolabelled bleomycin was present at 
higher concentrations in the medium as compared to that in the cells even after 
several hours of treatment (Lyman et al., 1986; Ozawa et al., 1988; Roy and 
Horwitz, 1984). In addition, the ability of bleomycin to induce cell 
morphological changes associated with apoptosis correlates with the number 
of bleomycin molecules that has been internalized by the cells (Tounekti et al., 
1993). DDR was significantly enhanced in bleomycin-treated cells when the 
cells were pre-treated with a general permeabilizing agent, 
lysophosphatidylcholine (Sidik and Smerdon, 1990). The inefficient uptake of 
bleomycin by the cells may therefore account for the delay in apoptosis as 
shown in our study.  
Like bleomycin, doxorubicin also induces DDR signaling in the 
primary murine fibroblasts (data not shown). Doxorubicin is anthracycline 
drug that is isolated from Streptomyces peucetius var. caesius. It is classically 
known as a topoisomerase II poison, and is routinely used in combination 
regimes with other chemotherapeutic drugs for treatment of breast, lung, 
gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple 
myeloma, sarcoma, and pediatric cancers (Arcamone et al., 1969; Cortes-
Funes and Coronado, 2007; Weiss, 1992). Interestingly, studies have showed 
that similar to bleomycin, doxorubicin can also induce genotoxic stress by 
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generating free radicals other than by inhibiting DNA topoisomerase II. This 
process occurs when doxorubicin is oxidized to an unstable metabolite 
(semiquinone), and then reverts back to doxorubicin, thus releasing reactive 
oxygen species in the process that damage the membranes, DNA and proteins, 
therefore triggering cell death (Doroshow, 1986). It would therefore be 
worthwhile to study if IL-1Ra secretion is dependent on the activity of the 
reactive oxygen species generated by bleomycin or doxorubicin. 
IL-1Ra is a naturally occurring inhibitor of IL-1 as it competes with 
IL-1 for binding onto IL-1R1. In addition, IL-1Ra is inducible by IL-1 
signaling as well as by other pro-inflammatory stimuli such as LPS or IgG 
complexes that induce IL-1 expression (Arend et al., 1998). Studies have also 
shown that infusion of either IL-1α or IL-1β in humans for 15 minutes resulted 
in a dramatic increase in IL-1Ra levels after an hour (Bargetzi et al., 1993; 
Kopp et al., 1996). Our findings demonstrated that genotoxic stress induces 
IL-1Ra secretion, but not IL-1R1 protein expression. Although we were 
unable to detect IL-1α and IL-1β in our system, our data suggests that IL-1β 
mRNA levels were induced in respond to bleomycin. IL-1 however, does not 
play a role in regulating IL-1Ra secretion in response to genotoxic stress as 
blocking of either IL-1α or IL-1β did not impair the secretion of IL-1Ra. 
Moreover, abrogation of IL-1R1 did not impair IL-1Ra secretion due to 
bleomycin. These findings indicate that genotoxic stress-induced IL-1Ra 
secretion is independent of IL-1 signaling. 
In this study, we showed that genotoxic stress due to chemotherapy 
activates the intrinsic apoptosis pathway but not the extrinsic apoptosis 
pathway. In addition, caspases mediating this pathway are important in 
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regulating IL-1Ra secretion induced by bleomycin. Caspases have previously 
been shown to play a role in regulating other members of the IL-1 family. In 
particular, caspase-1 is established to be responsible for IL-1β processing and 
maturation (Martinon et al., 2009). Caspase-1 is also the key molecule that 
mediates pyroptosis, a unique form of cell death that occurs when 
macrophages are infected with intracellular bacteria. Besides pro-IL-1β, 
caspase-1 also regulates the secretion of several other pro-inflammatory 
cytokines such as pro-IL-18. In contrast, proteolytic cleavage of IL-33 
precursor by caspase-1 or caspase-3 inactivates it instead (Cayrol and Girard, 
2009). In addition, increasing body of evidence show that there is crosstalk 
between inflammatory and apoptosis pathways, such as the role of caspase-8 
in IL-1β processing and activation (Latz et al., 2013). The activation of IL-1β 
by caspase-8 can be triggered by various ways. Firstly, sensing of fungal 
components by PRR dectin 1 expressed by human DCs induces the formation 
of mucosa-associated lymphoid tissue lymphoma translocation protein 1 
(MALT1)-ASC-caspase-8 complex, which in turn mediates the cleavage and 
activation of IL-1β (Gringhuis et al., 2012). This complex is also known as a 
non-canonical caspase-8 inflammasome.  Secondly, pro-IL-1β is processed by 
caspase-8 when activated by TLR3- or TLR4-mediated TRIF signaling in the 
presence of cycloheximide (Maelfait et al., 2008). Activation of TNFR family 
such as CD95 has also been shown to trigger caspase-8-dependent processing 
of IL-1β and IL-18 (Bossaller et al., 2012; Miwa et al., 1998).  
Our data on the role of caspases in regulating IL-1Ra secretion in 
response to bleomycin, are also supported by other experiments that we had 
performed in this study. For instance, administration of cycloheximide, 
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tunicamycin or caffeine induced IL-1Ra secretion, while administration of 
both bleomycin and cycloheximide, tunicamycin or caffeine further enhanced 
the levels of secreted IL-1Ra. This may be due to the apoptotic effecs of 
cycloheximide, tunicamycin and caffeine on cells (Alessenko et al., 1997; He 
et al., 2003; Huang et al., 2009; Yazawa et al., 2001). For instance, 
tunicamycin can induce ER stress in a number of cell lines, which leads to 
activation of several caspases including caspase-3 and caspase-9 and 
eventually apoptosis after 24 hours of treatment (Huang et al., 2009). Caffeine 
on the other hand, induces caspase-3 activation in a dose- and time-dependent 
manner (He et al., 2003). In addition, KU-60019 and caffeine have been 
routinely used as radiosensitizers (Golding et al., 2009; Sarkaria et al., 1999), 
and can potentiate the effect of apoptosis when used in conjunction with 
bleomycin. This was demonstrated in a study where caffeine enhanced the 
DNA damaging effects of bleomycin by increasing the number of bleomycin-
induced chromosomal aberrations in cell culture (Kihlman et al., 1974). 
We observed that inhibiting caspase-9 has a greater effect on 
bleomycin-induced IL-1Ra secretion as compared to caspase-3 inhibition. 
Studies have shown that caspase-9 is positioned at the pivotal junction within 
the intrinsic apoptosis pathway, and is therefore regarded as the key caspase of 
this pathway (Nunez et al., 1998; Thornberry and Lazebnik, 1998). In contrast, 
caspase-3 is activated downstream of caspase-9 and is the point of 
convergence for both extrinsic and intrinsic pathways. Like caspase-7 and 
caspase-6, caspase-3 acts an effector caspase that executes the process of 
apoptosis and amplifies the caspase-8 and/or caspase-9 initiation signals into 
commitment to apoptosis. Although caspase-3 and caspase-7 are found to 
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perform distinct roles, past findings suggests that these two highly 
homologous caspases share overlapping functions in apoptosis and have 
common substrate preferences such as PARP (Walsh et al., 2008). For 
instance, mice on mixed 129X1/SvJ and C57BL/6J backgrounds that are 
deficient in caspase-3 died prenatally due to neuronal hyperplasia (Kuida et 
al., 1996). In contrast, caspase-3 knockout mice on pure C57BL/6J 
background are viable (Leonard et al., 2002), possibly due to overlapping 
functions of caspase-7 with caspase-3 and therefore compensate for the 
absence of caspase-3. Moreover, caspase-7 is expressed at higher constitutive 
levels in C57BL/6J, and may ameliorate the caspase-3 knockout phenotype in 
these mice (Lakhani et al., 2006). 
A recent study showed that IL-1Ra protein expression was upregulated 
in the heart explants of patients with end stage ischemic heart disease and the 
gene expression of both sIL-1Ra and icIL-1Ra isoforms was increased (Vecile 
et al., 2013). Moreover, exposing cardiomyocytes to hypoxia conditions 
activated caspase-9, followed by caspase-3, caspase-7 and caspase-6, leading 
to apoptosis (de Moissac et al., 2000; Narula et al., 1999; Vecile et al., 2013). 
Interestingly, both sIL-1Ra and icIL-1Ra isoforms were found to interact with 
caspase-9 and caspase-3, and to a lesser degree, with caspase-7 and caspase-6. 
Interaction of IL-1Ra with the caspases in turn, limits caspase activities, 
suggesting that IL-1Ra has anti-apoptotic effects. Indeed, cardiomyocytes that 
were deficient for IL-1Ra were more susceptible to hypoxia-induced cell death 
as compared to the wild-type cells and genetic inhibition of IL-1Ra enhanced 
caspase activities. The anti-apoptotic effects of IL-1Ra have also been 
demonstrated in other studies (Nesic et al., 2001; Sun et al., 2006). The 
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mechanism of IL-1Ra induction by hypoxia however, is likely to be different 
from our study because an increase in IL-1Ra mRNA levels was detected in 
the myocardial specimens harvested from heart explants for ischemic 
cardiomyopathy. Nevertheless, these findings suggest that IL-1Ra may have 
inhibitory effects on caspase activation and delays bleomycin-induced 
apoptosis as shown in our study. Further investigation is necessary in order to 
determine the potential inhibitory effect of IL-1Ra on caspase activity. 
Although the role of p53 in the intrinsic apoptosis pathway has been 
well established, abrogation of p53 did not prevent the increase in IL-1Ra 
release by bleomycin-treated cells, suggesting that bleomycin-induced IL-1Ra 
release is independent of p53 activity. Moreover, we did not see any 
significant difference in apoptosis between p53-deficient cells and wild-type 
cells after bleomycin treatment (data not shown). This suggests that in the 
absence of p53, cells can still die by apoptosis independently of p53 signaling. 
Indeed, studies have shown that p73, a highly homologous protein to p53, can 
transactivate a subset of p53 responsive genes that are responsible for 
mediating growth arrest and apoptosis (Melino et al., 2002). These genes 
include pro-apoptotic proteins of the Bcl-2 family such as Bax and PUMA 
(Haupt et al., 2003; Thornborrow et al., 2002), which in turn mediate p73-
induced mitochondrial pathway irrespective of the p53 status (Melino et al., 
2004; Melino et al., 2003).  
The intrinsic apoptosis pathway is dependent on the permeabilization 
of the outer mitochondrial membrane, leading to the release of several pro-
apoptotic factors that are residing in the mitochondrial intermembrane space 
such as cytochrome c. In this study, we observed a steady loss of ΔΨm up to 
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48 hours of treatment with bleomycin, suggesting that bleomycin-induced 
apoptosis is intricately linked to mitochondrial dysfunction. Loss of ΔΨm 
occurs in a caspase-dependent or in a caspase-independent manner (Tait and 
Green, 2010). For the former, caspase-3 and caspase-7 enter the mitochondrial 
intermembrane space following the permeabilization of the outer 
mitochondrial membrane, and disrupt the proton gradient by cleaving one of 
the complexes that makes up the electron transport chain. This process 
releases ROS, resulting in the externalization of phosphatidylserine in the 
outer leaflet of the plasma membrane as well as in cell permeabilization. In 
contrast, the caspase-independent pathway occurs when the cytochrome c 
levels are limited. As cytochrome c acts as an electron carrier that shuttles 
electrons between the complexes of the electron transport chain, this prevents 
electron transfer and leads to the loss of ΔΨm (Christensen et al., 2013). 
Although the mitochondria can regenerate ΔΨm by using cytoplasmic 
cytochrome c, this is prevented during apoptosis as the proteolytic actions of 
caspases disrupt the electron transport chain.   
IL-1Ra exists in a number of isoforms, mainly the secreted isoform and 
the intracellular isoform. sIL-1Ra has a secretory leader peptide which is 
important for its release via the classical or ER-Golgi-dependent secretory 
pathway, and this is shown in LPS-treated human blood monocytes which 
express sIL-1Ra in the Golgi apparatus (Andersson et al., 1992). Secretion of 
sIL-1Ra occurs by translocation of the proteins across the ER membrane, 
followed by transportation through the Golgi apparatus to the plasma 
membrane. The latter process occurs directly or is mediated via secretory 
granules (Eder, 2009). Alternative splicing of an upstream exon of sIL-1Ra 
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generates the type 1 intracellular IL-1Ra (icIL-1Ra1). This 18 kDa protein is 
mainly expressed in keratinocytes, endothelial cells and monocytes (Haskill et 
al., 1991). Type 2 icIL-1Ra (icIL-1Ra2) isoform on the other hand, has not 
been detected in human cells (Muzio et al., 1995). Type 3 icIL-1Ra (icIL-
1Ra3) is a 15 kDa protein that is mainly expressed by monocytes, 
macrophages, neutrophils and hepatocytes. It is generated by alternative 
splicing and by alternative translation initiation from sIL-1Ra mRNA (Bonay 
et al., 1997; Malyak et al., 1998). Unlike sIL-1Ra however, icIL-1Ra isoforms 
do not possess the conventional hydrophobic signal peptides, and are likely to 
be released in a non-conventional manner. Our findings have shown that IL-
1Ra secretion induced by bleomycin is unaffected by both brefeldin A and 
monensin, which inhibits the anterograde transport of proteins between ER 
and the Golgi apparatus and disrupts the proton gradient across the trans-
Golgi network respectively. Moreover, inhibition of N-link protein 
glycosylation did not impair bleomycin-induced IL-1Ra secretion. It is 
therefore plausible that icIL-1Ra is the isoform that is being released by the 
cells in response to bleomycin via the leaderless pathway. In addition, we 
observed that bleomycin-treated cells continued to release IL-1Ra even after 
48 hours of treatment despite the significant reduction in IL-1Ra mRNA 
levels, suggesting that IL-1Ra may be derived from a pool of proteins that is 
readily released in response to genotoxic stress. 
Although sIL-1Ra is the only protein in the IL-1 family that possesses 
a classical signal peptide, several studies have detected leaderless IL-1 family 
members in the culture supernatants as well. In fact, it is well established that 
IL-1β is secreted via the leaderless pathway. It was first suggested that IL-1β 
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is released in a non-conventional manner when brefeldin A or monensin did 
not affect IL-1β secretion (Rubartelli et al., 1990). Since then, multiple 
mechanisms have been suggested for the secretion of IL-1β, including (1) loss 
of membrane integrity resulting in the leakage of intracellular contents, (2) 
exocytosis of the secretory lysosomes (Andrei et al., 2004), (3) release of IL-
1β-containing plasma membrane microvesicles (4) exocytosis of the 
exosomes, or (5) export via specialized transporters through the plasma 
membrane (Eder, 2009). Shedding of the microvesicles involves the release of 
membrane-bound pro-IL-1β, mature IL-1β and caspase-1 in a calcium-
dependent manner (MacKenzie et al., 2001). This process is initiated when 
ATP binds to the P2X7 receptor. Translocation of phosphatidylserine occurs 
from the inner side of the plasma membrane to outside during formation of the 
microvesicles, which perturbs the lipid symmetry of the plasma membrane 
(Bianco et al., 2005; MacKenzie et al., 2001; Pizzirani et al., 2007). 
Interestingly, pro-IL-1β was detected in the microvesicles soon after P2X7 
receptors were activated, while mature IL-1β was only detected much later. 
This suggests that pro-IL-1β was processed only after the shedding 
microvesicles. One study has demonstrated that icIL-1Ra1 is released in an 
analogous manner, where stimulation of the P2X7 receptors induced icIL-
1Ra1 release by LPS-primed RAW 264.7 macrophages and endothelial cells 
derived from human umbilical vein, and the release of icIL-1Ra1 is impaired 
when the cells were pre-incubated with oxidized ATP, a calmodulin kinase II 
and P2X7 inhibitor (KN62) or ATPase (apyrase) (Wilson et al., 2004). 
Moreover, this study showed that icIL-1Ra1 is released via a P2X7R-
dependent microvesicle shedding mechanism.  
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Recently, autophagy has been proposed as a possible mechanism for 
the leaderless secretion of IL-1β (Carta et al., 2013). Autophagy is a 
homeostatic process that maintains cytosolic biosynthesis by catabolizing 
cellular organelles and proteins during starvation, and removes old organelles 
and aggregates that are beyond the capacity of other endogenous degradation 
mechanisms (Levine and Kroemer, 2008). Treatments that activate autophagy 
enhanced the secretion of a leaderless protein, Acb1. In addition, mutants that 
are deficient for various markers of autophagy have impaired Acb1 secretion 
(Duran et al., 2010; Manjithaya et al., 2010). Autophagy has therefore been 
proposed to be a possible mechanism for secretion of the leaderless IL-1β, 
where the previously identified secretory lysosomes that contain pro-IL-1β 
and caspase-1 may in fact be autophagosomes. To test the possibility that 
bleomycin-induced IL-1Ra secretion is indeed mediated via autophagy, we 
measured the effect of bleomycin on the expression levels of autophagosome 
markers, LC3 and p62. Cytosolic-associated protein light chain (LC3-I) is 
converted to the membrane-bound, lipidated form LC3-II by conjugation to 
phosphatidylethanolamine, and is recruited to the autophagosomes when 
autophagy is initiated (Matsushita et al., 2007). p62/SQSTM1 on the other, is 
an adaptor protein that binds to LC3-II and is degraded during autophagy 
(Mathew et al., 2009). When fibroblasts were treated with bleomycin, there 
were no observable changes in the expression levels of LC3-I, LC3-II and p62 
and pre-treatment of the cells with an autophagic sequestration blocker, 3-
methyladenine did not impair bleomycin-induced IL-1Ra secretion (data not 
shown). Our data hence suggest that bleomycin-induced IL-1Ra secretion is 
not mediated via autophagy. 
	  	   158 
Both primary murine fibroblasts and RAW 264.7 cells were induced to 
release IL-1Ra in response to genotoxic stress, and the secretion levels of IL-
1Ra increased steadily with time. Since IL-1Ra is a naturally occurring 
inhibitor of IL-1, our data suggest that genotoxic stress induces cells to release 
IL-1Ra to prevent or to dampen inflammatory responses. Indeed, we showed 
that IL-1Ra released in response to bleomycin is bioactive and impairs IL-1 
induced IL-6 gene expression. However, unresolved DNA damage may also 
lead to persistent DNA damage signaling that drives cells into senescence 
(Rodier et al., 2009). The initial anti-inflammatory effects of genotoxic stress 
may then be reduced as studies have shown that persistent DNA damage 
induces senescent cells to upregulate pro-inflammatory factors such as IL-1α 
and IL-1β. In addition, cell surface-bound IL-1α is shown to regulate the 
senescence-associated cytokine network in a juxtacrine manner (Orjalo et al., 
2009). The role of senescent cells in modulating their microenvironment is 
demonstrated in other studies where the senescent cells released pro-
inflammatory factors including IL-1, that activated immune cells and induced 
immune cell-mediated clearance of tumors (Krizhanovsky et al., 2008; 
Lujambio et al., 2013; Xue et al., 2007). In light of these data, we therefore 
propose that the immediate response of the cells to genotoxic stress is to 
release anti-inflammatory factors like IL-1Ra in order to prevent or to dampen 
inflammatory responses. Cells with DNA lesions that are too extensive to be 
repaired, are subsequently induced to die by apoptosis. Conversely, damaged 
cells that did not die but are unsuccessful in repairing the DNA damage, enter 
cellular senescence instead. These senescent cells then secrete pro-
inflammatory cytokines that recruit and activate immune cells that help to 
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clear the senescent cells. More experiments would be necessary in order to 
understand the effects of genotoxic stress on the development and progression 
of inflammatory responses, as well as the consequences of such changes on 
the immune system. 
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10.3 Role of IL-1 in Eµ-myc-induced murine B cell leukemia 
Our findings established a link between genotoxic stress and IL-1Ra release, 
which in turn impairs IL-1 signaling. Likewise, other studies also suggest that 
genotoxic stress and the ensuing DDR are intricately linked to IL-1 signaling 
which in turn, may promote or prevent cancer progression (Lujambio et al., 
2013; Rodier et al., 2009). To investigate the physiological relevance of IL-1 
signaling in vivo, we monitored the effects of abrogating IL-1R1 on 
tumorigenesis in the Eµ-myc mice. These mice overexpress the c-Myc 
oncogene under the control of Ig heavy chain enhancer and the B220low tumor 
cells have sustained genotoxic stress (Adams et al., 1983; Pusapati et al., 
2006; Ray et al., 2006). The mutant mice eventually develop spontaneous 
immature B cell lymphomas, which are analgous to human Burkitt lymphoma 
(Adams et al., 1983). Previously, our lab has reported that majority of the Eµ-
myc mice exhibited a spontaneous reduction in blood tumor cells between 41 – 
65 days of age (Croxford et al., 2013). This is mainly mediated by extrinsic 
mechanisms, as spontaneous regression of blood tumors was impaired in Eµ-
myc mice that were depleted for NK and/or T cells.  
In this study, we showed that the survival times for the Il1r1-/-, Eµ-
myc+/- mice were not significantly different from that for the Il1r1+/+, Eµ-
myc+/- mice. Moreover, ablation of IL-1R1 did not affect extrinsic 
immunosurveillance mechanisms in the Eµ-myc mice, as Il1r1+/+, Eµ-myc+/- 
mice and Il1r1-/-, Eµ-myc+/- mice displayed spontaneous regression in blood 
tumor levels. Although T cells have previously been shown to respond to IL-1 
(Ben-Sasson et al., 2009; Lichtman et al., 1988; Williams et al., 1991), no IL-
1R1 expression was detected on the CD8+ and CD4+ T cells that were derived 
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from the Il1r1+/+, Eµ-myc+/- mice. NK1.1+ cells from these mice too did not 
express detectable levels of IL-1R1. This suggests that the immune-mediated 
extrinsic mechanisms are independent of IL-1R1 signaling. Interestingly, the 
percentage of IgM- B220low cells was significantly higher in the Il1r1-/-, Eµ-
myc+/- mice as compared to the Il1r1+/+, Eµ-myc+/- mice, and may account for 
the delay in tumor regression in the Il1r1-/-, Eµ-myc+/- mice. As we could not 
detect IL-1R1 expression on the B cells derived from Il1r1+/+, Eµ-myc+/- mice, 
it is unlikely that IL-1 will have any direct effect on B cell proliferation 
(Maliszewski et al., 1990; Rousset et al., 1991).. It remains to be determined if 
the spontaneous loss of IgM- B220low cells during the regression period is a 
direct or indirect consequence of IL-1R1 signaling. 
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10.4 Additive anti-cancer effects of inflammatory inducers and 
chemotherapy on Eµ-myc-induced murine B cell leukemia 
While our earlier findings indicate that genotoxic stress mediates 
inflammatory responses by regulating IL-1Ra secretion, inflammatory factors 
in turn may also influence the immunomodulatory effects of genotoxic stress 
caused by chemotherapy. Here we showed that the TLR1/2 agonist, 
Pam3CSK4 enhances the anti-cancer effects of Ara-C by inducing tumor cells 
to upregulate several co-stimulatory molecules, therefore increasing the 
immunogenicity of these tumor cells. This is in line with the findings from 
another study, which showed that combined treatment of a TLR9 agonist, 
CpG-oligodeoxynucleotide (CpG-ODN) with Nutlin-3, a potent activator of 
p53, increased immune activation in the B-chronic lymphocytic leukemic (B-
CLL) cells (Secchiero et al., 2008). In particular, CD80 plays a critical role in 
anti-cancer immune responses mediated by NK and T cells (Chan et al., 2012; 
Kelly et al., 2002; Nakazaki et al., 1998; Raulet et al., 2013), and transduction 
of acute myeloid leukemia cells with a lentivirus encoding CD80 and IL-2 
increases their sensitivity to NK and T cell cytotoxicity (Chan et al., 2005; 
Ingram et al., 2009).  
In addition, we observed that mice that received Pam3CSK4 and Ara-C-
treated EµM2 cells had significantly prolonged lifespan as compared to the 
mice that received Pam3CSK4 or Ara-C-treated EµM2 cells. This correlated 
with a significantly reduced tumor burden in the spleen as well as in the blood 
in mice that received Pam3CSK4 and Ara-C-treated EµM2 cells. Reduced 
tumorigenicity of co-treated tumor cells is unlikely to be a result of cell 
intrinsic tumor-suppressor mechanisms as pre-treatment of EµM2 cells with 
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Pam3CSK4 followed by Ara-C did not significantly affect the percentage of 
apoptotic cells as compared to Ara-C treatment alone (data not shown). Based 
on our in vitro findings, the combination therapy increased the 
immunogenicity of EµM2 cells, thus leading to enhanced immune recognition 
and clearance of the tumor cells by immune cells such as NK and T cells. 
Indeed, a previous study that investigated the effects of administering CpG-
ODN in combination with chemotherapeutic agents in an orthotopic murine 
model of rhabdomyosarcoma, found that T cells contributed to the protective 
effects of this combination treatment (Weigel et al., 2003). Although CD8+ T 
cells are critical for immunosurveillance, recent evidence has also uncovered 
an important role for CD4+ T cells in anti-cancer immune responses 
(Porakishvili et al., 2004; Quezada et al., 2010; Yasukawa et al., 1996). For 
instance, the clearance of a bladder carcinoma cell line depends on CD4+ T 
cells and NK cells (Perez-Diez et al., 2007), while tumor-reactive CD4+ T 
cells were found to develop cytotoxic activity and to eradicate established 
melanoma (Quezada et al., 2010; Xie et al., 2010). Finally, CD4+ T cells are 
associated with tumor regression upon Myc inactivation (Rakhra et al., 2010). 
We have demonstrated that the additive effects of Pam3CSK4 and 
Ara-C treatment are mediated by NF-κB. TLR2 forms a heterodimer with 
TLR1 in response to Pam3CSK4 leading to the recruitment of the adaptor 
proteins MAL and MYD88 and the activation of IRAK4, IRAK1, and TRAF6 
(Kawai and Akira, 2007). Phosphorylated IRAK1 and TRAF6 then dissociate 
from the receptor and form a complex with TAK1, TAB1 and TAB2, leading 
to the subsequent activation of NF-κB. Interestingly, DNA lesions in response 
to DNA damaging agents are also shown to activate NF-κB via ATM-
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dependent phosphorylation and ubiquitylation of NEMO (Miyamoto, 2011). 
Similar to TLR2 signals, ATM-driven NF-κB activation depends on TRAF6, 
TAK1 and TAB2. Hence, it is likely that Pam3CSK4 and Ara-C signals 
combine at the levels of TAK1/TAB-mediated activation of NF-κB. 
Our study offers an attractive alternative cancer therapy that is 
potentially more efficacious than the current chemotherapy regime for non-
Hodgkin B cell lymphoma. The combined usage of Pam3CSK4 and Ara-C 
increased the anti-cancer response observed with either Pam3CSK4 or Ara-C 
single treatments. Since Pam3CSK4 is a potent activator of innate immune 
cells and these cells are the first to regain function after chemotherapy, it may 
be feasible to develop such combination therapies for future clinical 
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